1
|
Walls GM, O'Connor J, Harbinson M, Duane F, McCann C, McKavanagh P, Johnston DI, Giacometti V, McAleese J, Hounsell AR, Cole AJ, Butterworth KT, McGarry CK, Hanna GG, Jain S. The Association of Incidental Radiation Dose to the Heart Base with Overall Survival and Cardiac Events after Curative-intent Radiotherapy for Non-small Cell Lung Cancer: Results from the NI-HEART Study. Clin Oncol (R Coll Radiol) 2024; 36:119-127. [PMID: 38042669 DOI: 10.1016/j.clon.2023.11.029] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2023] [Revised: 10/10/2023] [Accepted: 11/06/2023] [Indexed: 12/04/2023]
Abstract
AIMS Cardiac disease is a dose-limiting toxicity in non-small cell lung cancer radiotherapy. The dose to the heart base has been associated with poor survival in multiple institutional and clinical trial datasets using unsupervised, voxel-based analysis. Validation has not been undertaken in a cohort with individual patient delineations of the cardiac base or for the endpoint of cardiac events. The purpose of this study was to assess the association of heart base radiation dose with overall survival and the risk of cardiac events with individual heart base contours. MATERIALS AND METHODS Patients treated between 2015 and 2020 were reviewed for baseline patient, tumour and cardiac details and both cancer and cardiac outcomes as part of the NI-HEART study. Three cardiologists verified cardiac events including atrial fibrillation, heart failure and acute coronary syndrome. Cardiac substructure delineations were completed using a validated deep learning-based autosegmentation tool and a composite cardiac base structure was generated. Cox and Fine-Gray regressions were undertaken for the risk of death and cardiac events. RESULTS Of 478 eligible patients, most received 55 Gy/20 fractions (96%) without chemotherapy (58%), planned with intensity-modulated radiotherapy (71%). Pre-existing cardiovascular morbidity was common (78% two or more risk factors, 46% one or more established disease). The median follow-up was 21.1 months. Dichotomised at the median, a higher heart base Dmax was associated with poorer survival on Kaplan-Meier analysis (20.2 months versus 28.3 months; hazard ratio 1.40, 95% confidence interval 1.14-1.75, P = 0.0017) and statistical significance was retained in multivariate analyses. Furthermore, heart base Dmax was associated with pooled cardiac events in a multivariate analysis (hazard ratio 1.75, 95% confidence interval 1.03-2.97, P = 0.04). CONCLUSIONS Heart base Dmax was associated with the rate of death and cardiac events after adjusting for patient, tumour and cardiovascular factors in the NI-HEART study. This validates the findings from previous unsupervised analytical approaches. The heart base could be considered as a potential sub-organ at risk towards reducing radiation cardiotoxicity.
Collapse
Affiliation(s)
- G M Walls
- Cancer Centre Belfast City Hospital, Belfast Health & Social Care Trust, Belfast, UK; Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK.
| | - J O'Connor
- Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK
| | - M Harbinson
- Department of Cardiology, Belfast Health & Social Care Trust, Belfast, UK; Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK
| | - F Duane
- St. Luke's Radiation Oncology Network, St. Luke's Hospital, Dublin, Ireland; Trinity St James's Cancer Institute, St. James's Hospital, Dublin, Ireland
| | - C McCann
- Department of Cardiology, Belfast Health & Social Care Trust, Belfast, UK
| | - P McKavanagh
- Department of Cardiology, Ulster Hospital, South Eastern Health & Social Care Trust, Dundonald, UK
| | - D I Johnston
- Cancer Centre Belfast City Hospital, Belfast Health & Social Care Trust, Belfast, UK
| | - V Giacometti
- Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK
| | - J McAleese
- Cancer Centre Belfast City Hospital, Belfast Health & Social Care Trust, Belfast, UK
| | - A R Hounsell
- Cancer Centre Belfast City Hospital, Belfast Health & Social Care Trust, Belfast, UK; Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK
| | - A J Cole
- Cancer Centre Belfast City Hospital, Belfast Health & Social Care Trust, Belfast, UK; Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK
| | - K T Butterworth
- Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK
| | - C K McGarry
- Cancer Centre Belfast City Hospital, Belfast Health & Social Care Trust, Belfast, UK; Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK
| | - G G Hanna
- Cancer Centre Belfast City Hospital, Belfast Health & Social Care Trust, Belfast, UK; Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK
| | - S Jain
- Cancer Centre Belfast City Hospital, Belfast Health & Social Care Trust, Belfast, UK; Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK
| |
Collapse
|
2
|
Xie L, O'Connor J, Albert S, Gary-Webb T, Sharbaugh M, Donohue JM, Ennis M, Hutcheson D, Cole ES. Churn in Supplemental Nutrition Assistance Program: Changes in Medicaid Expenditure and Acute Care Utilization. Med Care 2024; 62:3-10. [PMID: 37449863 DOI: 10.1097/mlr.0000000000001887] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/18/2023]
Abstract
BACKGROUND The Supplemental Nutrition Assistance Program (SNAP) provides financial assistance to low-income individuals and families to help them purchase food. However, when participants experience short-term disenrollment from the program, known as churn, it can disrupt their health care usage patterns or result in acute health care needs due to the loss of financial benefits and time burden required to reapply for SNAP. OBJECTIVE The objective of this study was to examine the changes in health care expenditures and acute care utilization during periods of SNAP churn compared with nonchurn periods among those who churn during the study period. RESEARCH DESIGN Longitudinal analysis of Pennsylvania Medicaid claims data for enrollees participating in SNAP between 2016 and 2018 using individual fixed-effects models. We add to the literature by estimating whether these changes varied based on the amount of SNAP benefit lost, or differed between adults and children. RESULTS We found that SNAP churn was associated with reductions in pharmacy and primary care spending across all SNAP benefit levels and age groups. Specifically, our findings indicate a reduction of 4%-6% in pharmacy expenditures for adults and 2%-4% for children. Moreover, there was a 3%-4% decrease in primary care expenditures for adults and a 4%-6% decrease for children. Acute care utilization did not significantly change during a SNAP churn period. CONCLUSION Our findings of decreases in pharmacy and primary care spending suggest that preventing SNAP churn may help reduce instances where adult and child participants forgo necessary care.
Collapse
Affiliation(s)
- Liyang Xie
- NORC at the University of Chicago, Bethesda, MD
| | - Jason O'Connor
- Department of Health Policy and Management, University of Pittsburgh, Pittsburgh, PA
| | - Steven Albert
- Department of Behavioral and Community Health Sciences, University of Pittsburgh, Pittsburgh, PA
| | - Tiffany Gary-Webb
- Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA
| | - Michael Sharbaugh
- Department of Health Policy and Management, University of Pittsburgh, Pittsburgh, PA
| | - Julie M Donohue
- Department of Health Policy and Management, University of Pittsburgh, Pittsburgh, PA
| | - Molly Ennis
- Department of Health Policy and Management, University of Pittsburgh, Pittsburgh, PA
| | - Deborah Hutcheson
- Department of Sports Medicine and Nutrition, University of Pittsburgh, Pittsburgh, PA
| | - Evan S Cole
- Department of Health Policy and Management, University of Pittsburgh, Pittsburgh, PA
| |
Collapse
|
3
|
Walls G, O'Connor J, Harbsinson M, Duane FK, McCann C, McKavanagh P, Johnston D, Giacometti V, McAleese J, Hounsell A, Cole A, Butterworth K, McGarry C, Hanna GG, Jain S. Patient-Level and Endpoint-Specific Clinico-Dosimetric Analysis of the Cardiac Base as a Mediator of Radiation Cardiotoxicity in Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2023; 117:e69-e70. [PMID: 37786026 DOI: 10.1016/j.ijrobp.2023.06.800] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Cardiac disease is a dose-limiting toxicity in non-small cell lung cancer (NSCLC) radiation therapy. Radiation dose to the cardiac base is associated with poor overall survival in several clinical studies, but has not been validated in a non-dose escalated cohort, or with individual patient delineations. In this study we examined the impact of cardiac base dose on overall survival (OS) and cardiac events (CEs), and interrogated the relationships of the substructures comprising the heart base with OS and CEs. MATERIALS/METHODS Patients with stage I-III NSCLC treated with curative-intent radiation therapy between 2015 and 2020 at a regional cancer center were identified. Clinical notes were examined for baseline patient, tumor and cardiac details, and both cancer and cardiac outcomes. Three cardiologists verified CEs. Cardiac delineations were completed using a validated deep learning-based autosegmentation tool. Cox and Fine and Gray regressions were undertaken for the risk of death and CEs respectively, accounting for pre-specified evidence-based dose metrics and clinically relevant cardiac covariates. RESULTS Most patients received 55 Gy/20# (n = 461/478, 96%) without chemotherapy (58%), planned with VMAT (51%) or IMRT (20%). Pre-existing cardiovascular morbidity was common, with 78% having ≥2 risk factors, and 46% having >1 established cardiac disease. The median follow-up was 21.1 months. Dichotomized at the median, higher heart base Dmax was associated with poorer survival on Kaplan-Meier analysis (21.6 months (95% CI 19.3-24.9) versus 29.4 months (95% CI 21.6-36.6), p = 0.021), and remained significant when statistically compared in published multivariate models. In a multivariate analysis for pooled acute CEs, heart base Dmax was associated with CEs (HR 1.75, 95% CI 1.01-1.06, p = 0.04), but this was not the case for individual CEs. Using Fine and Gray models to account for the competing risk of death, left main coronary maximum dose was associated with atrial fibrillation (p = 0.024), proximal right coronary artery V15 (p = 0.023) and mean dose (p = 0.032), and the right atrium mean dose (p = 0.029) were associated with heart failure. No dose-volume metrics were significantly associated with acute coronary syndrome. None of the constituent base substructures dose were significantly associated with death. CONCLUSION Dose to the heart base was associated with increased mortality and an increased pooled cardiac event rate. Accounting for endpoint-specific clinical covariates, only select constituent substructures of the heart base were associated with CEs and no substructures were independently associated with survival. Together, these findings are suggestive of possible interplay between the constituent base substructures in their mediation of radiation cardiotoxicity.
Collapse
Affiliation(s)
- G Walls
- Patrick G Johnston Centre for Cancer Research, Belfast, United Kingdom
| | - J O'Connor
- Patrick G Johnston Centre for Cancer Research, Belfast, United Kingdom
| | - M Harbsinson
- Belfast Health & Social Care Trust, Belfast, United Kingdom
| | - F K Duane
- Trinity St James's Cancer Institute, St James's Hospital, Dublin, Ireland
| | - C McCann
- Belfast Health & Social Care Trust, Belfast, United Kingdom
| | - P McKavanagh
- South Eastern Health & Social Care Trust, Belfast, United Kingdom
| | - D Johnston
- Belfast Health & Social Care Trust, Belfast, United Kingdom
| | - V Giacometti
- Patrick G Johnston Centre for Cancer Research, Belfast, United Kingdom
| | - J McAleese
- Belfast Health & Social Care Trust, Belfast, United Kingdom
| | - A Hounsell
- Patrick G Johnston Centre for Cancer Research, Belfast, United Kingdom
| | - A Cole
- Patrick G Johnston Centre for Cancer Research, Belfast, United Kingdom
| | - K Butterworth
- Patrick G Johnston Centre for Cancer Research, Belfast, United Kingdom
| | - C McGarry
- Patrick G Johnston Centre for Cancer Research, Belfast, United Kingdom
| | - G G Hanna
- Patrick G Johnston Centre for Cancer Research, Belfast, United Kingdom
| | - S Jain
- Patrick G Johnston Centre for Cancer Research, Belfast, United Kingdom
| |
Collapse
|
4
|
Whitlow S, Haughey A, O'Connor J, Killeen RP. Prevalence of significant pathology on MRI of brain and orbits in patients presenting with visual disturbance. Eur J Ophthalmol 2023; 33:1834-1840. [PMID: 36862593 DOI: 10.1177/11206721231160990] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/03/2023]
Abstract
PURPOSE The aim of our study was to determine the frequency and variety of abnormalities detected on MRI studies of the brain and orbits (MRBO), in patients referred for investigation of visual disturbance from a tertiary ophthalmology centre in Ireland. A secondary objective was to assess the various imaging pathologies identified in this cohort of patients. METHODS The inclusion criteria were patients who underwent an Magnetic resonance imaging (MRI) brain or MRI brain and orbits over a 12-month period for investigation of first episode of visual disturbance, who were over 18 years of age, with visual disturbance of unknown aetiology. Statistical analysis was performed to calculate the percentage of abnormalities and corresponding 95% confidence interval (CI). Additionally, logistic regression was used to investigate any association between age, gender and the pathologies which presented. RESULTS 135 MRI brain and orbit examinations fulfilled the inclusion criteria. Abnormalities were identified on 86 of the 135 examinations (63.7%; 95% CI: 55.3% to 71.3%). Nonspecific T2 hyperintensities were identified on 28 (20.7%) of the examinations, 13 (9.6%) examinations showed images suggestive of demyelination and 11 (8.1%) showed optic neuropathy. The logistic regression analysis showed no evidence of an association between age (p = 0.223), gender (p = 0.307) and abnormalities in this study. CONCLUSION This represents a relatively high detection rate of abnormalities on MRBO when compared with similar studies and shows the important role MRI has in patients with a visual disturbance.
Collapse
Affiliation(s)
- S Whitlow
- Royal Victoria Eye and Ear Hospital, Dublin 2, Ireland
| | - A Haughey
- St. Vincent's University Hospital, Dublin 4, Ireland
| | - J O'Connor
- Royal Victoria Eye and Ear Hospital, Dublin 2, Ireland
| | - R P Killeen
- St. Vincent's University Hospital, Dublin 4, Ireland
| |
Collapse
|
5
|
Solomon KT, O'Connor J, Gibbons JB, Kilaru AS, Feder KA, Xue L, Saloner B, Stuart EA, Cole ES, Hulsey E, Meisel Z, Patel E, Donohue JM. Association Between Hospital Adoption of an Emergency Department Treatment Pathway for Opioid Use Disorder and Patient Initiation of Buprenorphine After Discharge. JAMA Health Forum 2023; 4:e230245. [PMID: 36961457 DOI: 10.1001/jamahealthforum.2023.0245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/25/2023] Open
Abstract
Importance Emergency department (ED)-based initiation of buprenorphine has been shown to increase engagement in outpatient treatment and reduce the risk of subsequent opioid overdose; however, rates of buprenorphine treatment in the ED and follow-up care for opioid use disorder (OUD) remain low in the US. The Opioid Hospital Quality Improvement Program (O-HQIP), a statewide financial incentive program designed to increase engagement in OUD treatment for Medicaid-enrolled patients who have ED encounters, has the potential to increase ED-initiated buprenorphine treatment. Objective To evaluate the association between hospitals attesting to an ED buprenorphine treatment O-HQIP pathway and patients' subsequent initiation of buprenorphine treatment. Design, Setting, and Participants This cohort study included Pennsylvania patients aged 18 to 64 years with continuous Medicaid enrollment 6 months before their OUD ED encounter and at least 30 days after discharge between January 1, 2016, and December 31, 2020. Patients with a claim for medication for OUD 6 months before their index encounter were excluded. Exposures Hospital implementation of an ED buprenorphine treatment O-HQIP pathway. Main Outcomes and Measures The main outcome was patients' receipt of buprenorphine within 30 days of their index OUD ED visit. Between August 2021 and January 2023, data were analyzed using a difference-in-differences method to evaluate the association between hospitals' O-HQIP attestation status and patients' treatment with buprenorphine after ED discharge. Results The analysis included 17 428 Medicaid-enrolled patients (female, 43.4%; male, 56.6%; mean [SD] age, 37.4 [10.8] years; Black, 17.5%; Hispanic, 7.9%; White, 71.6%; other race or ethnicity, 3.0%) with OUD seen at O-HQIP-attesting or non-O-HQIP-attesting hospital EDs. The rate of prescription fills for buprenorphine within 30 days of an OUD ED discharge in the O-HQIP attestation hospitals before the O-HQIP intervention was 5%. The O-HQIP attestation was associated with a statistically significant increase (2.6 percentage points) in prescription fills for buprenorphine within 30 days of an OUD ED discharge (β, 0.026; 95% CI, 0.005-0.047). Conclusions and Relevance In this cohort study, the O-HQIP was associated with an increased initiation of buprenorphine in patients with OUD presenting to the ED. These findings suggest that statewide incentive programs may effectively improve outcomes for patients with OUD.
Collapse
Affiliation(s)
| | - Jason O'Connor
- Department of Health Policy and Management, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland
| | - Jason B Gibbons
- Department of Health Policy and Management, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania
| | | | - Kenneth A Feder
- Department of Mental Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland
| | - Lingshu Xue
- Department of Health Policy and Management, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland
| | - Brendan Saloner
- Department of Health Policy and Management, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania
| | - Elizabeth A Stuart
- Department of Health Policy and Management, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania
| | - Evan S Cole
- Department of Health Policy and Management, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland
| | | | | | - Esita Patel
- Advanced Practice Outcomes and Analytics, The Center for Advanced Practice, Atrium Health Carolinas Medical Center, Charlotte, North Carolina
| | - Julie M Donohue
- Department of Health Policy and Management, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland
| |
Collapse
|
6
|
Thomas N, Stankard A, Cosgrave N, Conlon B, Monahan P, Halpin T, Britton D, Byrne P, McShane S, Sohail I, Grogan AM, Reilly A, Thapa A, Alsubaie N, Rane P, O'Connor J, Gray S, Kaja A, Gehani K, Kovalyshyn V, O'Brien H. 92 CONTINUING TO ‘BE HIP’: ORTHOGERIATRIC SERVICE IMPROVEMENTS IN 2021. Age Ageing 2022. [PMCID: PMC9620584 DOI: 10.1093/ageing/afac218.076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open
Abstract
Background Scotland first demonstrated that adherence to nationally agreed hip fracture standards improve patient survival, reduces the duration of admission, and reduces the need for high dependency care. Our study aims to assess adherence to the Irish Hip Fracture Standards (IHFS) in our hospital for 2021 amidst the COVID-19 pandemic, translating to improved clinical outcomes for our patients. Methods The IHF database was retrospectively analysed, comparing quarters 1-4 in 2021 with our 2020 results. Results IHFS1, patient time to the ward < 4hours, was maintained at 67% in 2021 versus 71% overall in 2020. There was improvement in IHFS2, time to surgery within 48 hours, up to 73% in 2021 versus 66% in 2020. IHFS3 was 4% in 2021 versus 3% overall in 2020. Further improvements were noted for IHFS4, with 95% of patients reviewed by a Geriatrician in 2021 versus 87% in 2020. IHFS5 also improved with 97% of patients receiving a bone health assessment in 2021 versus 87% in 2020. Moreover, IHFS6, improved with 97% of patients undergoing a specialised falls assessment in 2021 versus 87% in 2020. Conclusion The improvement in 2021 figures is reflective of the return of redeployed services during the COVID-19 pandemic inclusive of the Orthogeriatric Service, the Fracture Liaison Service Advanced Nurse Practitioner, the Trauma Co-ordinator, and the specialist Orthopaedic ward complete with its Orthopaedic nurses and Multi-Disciplinary Team, and improved Emergency Department pathways. These continued improvements in the IHFS further emphasise that success is dependent on a team that is joined at the hip
Collapse
Affiliation(s)
- N Thomas
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| | - A Stankard
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| | - N Cosgrave
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| | - B Conlon
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| | - P Monahan
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| | - T Halpin
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| | - D Britton
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| | - P Byrne
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| | - S McShane
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| | - I Sohail
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| | - AM Grogan
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| | - A Reilly
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| | - A Thapa
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| | - N Alsubaie
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| | - P Rane
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| | - J O'Connor
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| | - S Gray
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| | - A Kaja
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| | - K Gehani
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| | - V Kovalyshyn
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| | - H O'Brien
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| |
Collapse
|
7
|
Stankard A, Thomas N, Cosgrave N, Conlon B, Monaghan P, Halpin T, English D, Byrne P, McShane S, Sohail I, Grogan AM, Reilly A, Thapa A, Alsubaie N, Rane P, O'Connor J, Gray S, Kaja A, Gehani K, Kovalyshyn V, O'Brien H. 258 RISING TO THE CHALLENGE: ORTHOGERIATRIC SERVICE IMPROVEMENT AND COVID-19. Age Ageing 2022. [DOI: 10.1093/ageing/afac218.227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Nationally agreed hip fracture standards have contributed to the improvement of outcomes in hip fracture patients. In 2020, our hospital was awarded “The Golden Hip” for achieving highest compliance with Irish Hip Fracture Standards (IHFS) nationally for 2019.
Methods
Data from the Irish Hip Fracture Database (IHFD)was retrospectively analysed to assess our performance in 2020 versus 2019 in hip fracture patients over sixty. Multiple quality improvement interventions were put in place throughout 2019 to ensure improvement in IHFS1-6 compliance: Creation of the Hip Fracture Pathway Subgroup, IHFS 1 Breaches Audit, Orthogeriatric input at Orthopaedic inductions, weekly Multi-disciplinary Team meetings, a Nutritional Hip Fracture Pathway and addition of the Fracture Liaison Service Advanced Nurse Practitioner.
Results
There were 239 hip fracture patients in 2020 vs 249 in 2019. IHFS1 compliance improved with the percentage of patients admitted to the Orthopaedic ward within 4 hours increasing to 71% in 2020 from 56% in 2019. There was improvement in IHFS2-time to surgery <48 hours- 66% in 2020 vs 60% in 2019. IHFS3-pressure ulcer rate-was at the national average, 3% in 2020 vs 2% in 2019. IHFS4 (reviewed by a Geriatrician), IHFS5 (received a bone health assessment) and IHFS6 (received a specialised falls assessment) were lower overall; 87% in 2020 vs 98% in 2019. For all quarters (Q),43% of patients met all IHFS in our hospital in 2020 vs 32% in 2019, resulting in €90,000 in Best Practice Tariff funding.
Conclusion
Lower results for IHFS 4,5 and 6 reflect the arrival of the COVID-19 pandemic which led to redeployment of the Orthogeriatric Service and redeployment of the MDT from end of Q1 to Q3. When services in 2020 were preserved,1 in 2 hip fracture patients met all IHFS, vs 1 in 3 patients in 2019. Despite the pandemic, we continued to achieve the highest level of IHFS compliance nationally, being awarded a second consecutive “Golden Hip” for 2020.
Collapse
Affiliation(s)
- A Stankard
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| | - N Thomas
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| | - N Cosgrave
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| | - B Conlon
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| | - P Monaghan
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| | - T Halpin
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| | - D English
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| | - P Byrne
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| | - S McShane
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| | - I Sohail
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| | - AM Grogan
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| | - A Reilly
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| | - A Thapa
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| | - N Alsubaie
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| | - P Rane
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| | - J O'Connor
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| | - S Gray
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| | - A Kaja
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| | - K Gehani
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| | - V Kovalyshyn
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| | - H O'Brien
- Our Lady Of Lourdes Hospital , Drogheda, Ireland
| |
Collapse
|
8
|
Shirsath MA, O'Connor J, Boyle R, Newman L, Whelan R, Knight S, Meaney J, Kenny RA. 148 ORTHOSTATIC HEMODYNAMICS AND ACCELERATED BRAIN AGING. Age Ageing 2022. [DOI: 10.1093/ageing/afac218.125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Background
Impaired recovery of blood pressure (BP) in response to standing up is a prevalent condition in older individuals. We evaluated the relationship between the recovery of hemodynamic responses to standing and brain health in adults over 50.
Methods
Participants from The Irish Longitudinal Study on Aging (TILDA) (n=418) performed an active stand challenge while BP and heart rate (HR) were continuously monitored. The recovery of these parameters was determined as the difference in measurements taken at 10 s and 20 s after standing, in relation to the baseline value. The difference between biological and chronological brain age was determined using BrainPAD, a novel validated measure of accelerated brain ageing. The data was fitted using linear regression models, using age, sex, weight, height, cardiac disease prevalence, antihypertensive and antidepressant use, smoking status, standing speed and pulse wave velocity as covariates.
Results
Adjusting for age and sex only, each additional year of BrainPAD was associated with a –0.35 mmHg (95% CI: –0.54 – –0.16, P<.001) change in orthostatic systolic BP recovery. In a fully adjusted model, the regression coefficient was estimated at –0.29 mmHg (95% CI: –0.48 – –0.10, P<.01). Similarly, a year increase in BrainPAD was associated with –0.21 mmHg (95% CI: –0.32– –0.10, P<0.001) and –0.14 mmHg (95% CI: –0.25– –0.04, P<.01) change in orthostatic diastolic BP recovery, for minimally and fully adjusted models respectively. HR recovery was not significantly associated with BrainPAD.
Conclusion
These results demonstrate that impaired systolic and diastolic BP recovery after standing is associated with accelerated brain aging in older individuals. This suggests that the BP response to standing, measured using beat-to-beat monitoring, has potential to be used as a marker of accelerated brain aging, relying on a simple procedure and devices that are easily accessible for clinical use.
Collapse
Affiliation(s)
- MA Shirsath
- University of Dublin The Irish Longitudinal Study on Aging (TILDA), School of Medicine, Trinity College, , Dublin, Ireland
| | - J O'Connor
- Queen’s University School of Medicine, Dentistry and Biomedical Sciences, The Patrick G Johnston Centre for Cancer Research, , Belfast, United Kingdom
- University of Dublin The Irish Longitudinal Study on Aging (TILDA), School of Medicine, Trinity College, , Dublin, Ireland
| | - R Boyle
- University of Dublin Trinity College Institute of Neuroscience, Trinity College, , Dublin, Ireland
| | - L Newman
- University of Dublin The Irish Longitudinal Study on Aging (TILDA), School of Medicine, Trinity College, , Dublin, Ireland
| | - R Whelan
- University of Dublin Trinity College Institute of Neuroscience, Trinity College, , Dublin, Ireland
- Trinity College Dublin Global Brain Health Institute, Trinity College, , Dublin, Ireland
| | - S Knight
- University of Dublin The Irish Longitudinal Study on Aging (TILDA), School of Medicine, Trinity College, , Dublin, Ireland
| | - J Meaney
- St. James’s Hospital The National Centre for Advanced Medical Imaging (CAMI), , Dublin, Ireland
| | - RA Kenny
- University of Dublin The Irish Longitudinal Study on Aging (TILDA), School of Medicine, Trinity College, , Dublin, Ireland
| |
Collapse
|
9
|
Walls G, Giacometti V, Apte A, Thor M, McCann C, Hanna G, O'Connor J, Deasy J, Hounsell A, Butterworth K, Cole A, Jain S, McGarry C. P1.10-03 A Deep Learning Auto-Segmentation Tool for Cardiac Substructures in 4D Radiotherapy Planning for Locally Advanced Lung Cancer. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.181] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
10
|
Flattery A, McKiernan F, Browne J, Gray J, Zaid T, O'Connor J, Zintl A. The prevalence and distribution of Anaplasma phagocytophilum genotypes in Ixodes ricinus nymphs collected from farm- and woodland sites in Ireland. Ticks Tick Borne Dis 2022; 13:101928. [DOI: 10.1016/j.ttbdis.2022.101928] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2021] [Revised: 02/01/2022] [Accepted: 02/21/2022] [Indexed: 10/19/2022]
|
11
|
Zhou C, O'Connor J, Backen A, Valle JW, Bridgewater J, Dive C, Jayson GC. Plasma Tie2 trajectories identify vascular response criteria for VEGF inhibitors across advanced biliary tract, colorectal and ovarian cancers. ESMO Open 2022; 7:100417. [PMID: 35279528 PMCID: PMC9058891 DOI: 10.1016/j.esmoop.2022.100417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2021] [Revised: 01/10/2022] [Accepted: 01/19/2022] [Indexed: 12/02/2022] Open
Abstract
BACKGROUND Vascular endothelial growth factor inhibitors (VEGFi) are compromised by a lack of validated biomarkers. Previously we showed that changes in the concentration of plasma Tie2 (pTie2) was a response biomarker for bevacizumab. Here, we investigated whether pTie2 can predict response and progression cross-tumour for generic VEGFi treatment. PATIENTS AND METHODS Patients (n = 124) with advanced biliary tract cancer (ABC) received cisplatin/gemcitabine with cediranib or placebo (ABC-03 trial). Concentrations of pTie2 were measured longitudinally from before treatment until disease progression. Data from patients with ovarian cancer (n = 92, ICON7 trial) and patients with colorectal cancer (CRC) (n = 70, Travastin trial) were also included. RESULTS Cediranib-treated ABC patients were deconvoluted into distinct groups where in one group pTie2 trajectories resembled those seen in placebo-treated patients and in another pTie2 significantly reduced (t-test P = 2.7 × 10-14). Using the 95% confidence interval for these two groups, we defined a vascular complete response (vCR) as a 24% reduction in pTie2 within 9 weeks; vascular no response (vNR) as a 7% increase in pTie2, and a vascular partial response (between these limits). vCR cediranib-treated patients had significantly improved progression-free survival (8.8 versus 7.5 months, restricted mean ratio 0.73, P = 0.012) and overall survival (18.8 versus 12.1 months, hazard ratio 0.49, P = 0.02). By integrating data across ovarian cancer, CRC and ABC, we show that (i) patients with vNR do not benefit from VEGFi and (ii) Tie2-defined vascular progression occurs sufficiently in advance of radiological progressive disease that changes in treatment could be offered to prevent clinical deterioration. CONCLUSION pTie2 is the first cross-tumour, generic VEGFi, vascular response biomarker to guide optimum use of VEGFi in clinical practice.
Collapse
Affiliation(s)
- C Zhou
- CRUK Manchester Institute Cancer Biomarker Centre, University of Manchester, Manchester, UK
| | - J O'Connor
- Division of Cancer Sciences, University of Manchester, Manchester, UK; Division of Radiotherapy and Imaging, Institute of Cancer Research, London, UK
| | - A Backen
- Division of Cancer Sciences, University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester, UK
| | - J W Valle
- The Christie NHS Foundation Trust, Manchester, UK
| | - J Bridgewater
- University College Hospital Macmillan Cancer Centre, Huntley Street, London, UK
| | - C Dive
- CRUK Manchester Institute Cancer Biomarker Centre, University of Manchester, Manchester, UK
| | - G C Jayson
- Division of Cancer Sciences, University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester, UK.
| |
Collapse
|
12
|
Pinsker JE, Church MM, Brown SA, Voelmle MK, Bode BW, Narron B, Huyett LM, Lee JB, O'Connor J, Benjamin E, Dumais B, Ly TT. Clinical Evaluation of a Novel CGM-Informed Bolus Calculator with Automatic Glucose Trend Adjustment. Diabetes Technol Ther 2022; 24:18-25. [PMID: 34491825 PMCID: PMC8783627 DOI: 10.1089/dia.2021.0140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Background: Expert opinion guidelines and limited data from clinical trials recommend adjustment to bolus insulin doses based on continuous glucose monitor (CGM) trend data, yet minimal evidence exists to support this approach. We performed a clinical evaluation of a novel CGM-informed bolus calculator (CIBC) with automatic insulin bolus dose adjustment based on CGM trend used with sensor-augmented pump therapy. Materials and Methods: In this multicenter, outpatient study, participants 6-70 years of age with type 1 diabetes (T1D) used the Omnipod® 5 System in Manual Mode, first for 7 days without a connected CGM (standard bolus calculator, SBC, phase 1) and then for 7 days with a connected CGM using the CIBC (CIBC phase 2). The integrated bolus calculator used stored pump settings plus user-estimated meal size and/or either a manually entered capillary glucose value (SBC phase) or an imported current CGM value and trend (CIBC phase) to recommend a bolus amount. The CIBC automatically increased or decreased the suggested bolus amount based on the CGM trend. Results: Twenty-five participants, (mean ± standard deviation) 27 ± 15 years of age, with T1D duration 12 ± 9 years and A1C 7.0% ± 0.9% completed the study. There were significantly fewer sensor readings <70 mg/dL 4 h postbolus with the CIBC compared to the SBC (2.1% ± 2.0% vs. 2.8 ± 2.7, P = 0.03), while percent of sensor readings >180 and 70-180 mg/dL remained the same. There was no difference in insulin use or number of boluses given between the two phases. Conclusion: The CIBC was safe when used with the Omnipod 5 System in Manual Mode, with fewer hypoglycemic readings in the postbolus period compared to the SBC. This trial was registered at ClinicalTrials.gov (NCT04320069).
Collapse
Affiliation(s)
- Jordan E. Pinsker
- Sansum Diabetes Research Institute, Santa Barbara, California, USA
- Results of this study were presented in abstract form at the 14th International Conference on Advanced Technologies & Treatments for Diabetes, June 2021
| | - Mei Mei Church
- Sansum Diabetes Research Institute, Santa Barbara, California, USA
- Results of this study were presented in abstract form at the 14th International Conference on Advanced Technologies & Treatments for Diabetes, June 2021
| | - Sue A. Brown
- Division of Endocrinology, Center for Diabetes Technology, University of Virginia, Charlottesville, Virginia, USA
- Results of this study were presented in abstract form at the 14th International Conference on Advanced Technologies & Treatments for Diabetes, June 2021
| | - Mary K. Voelmle
- Division of Endocrinology, Center for Diabetes Technology, University of Virginia, Charlottesville, Virginia, USA
- Results of this study were presented in abstract form at the 14th International Conference on Advanced Technologies & Treatments for Diabetes, June 2021
| | - Bruce W. Bode
- Atlanta Diabetes Associates, Atlanta, Georgia, USA
- Results of this study were presented in abstract form at the 14th International Conference on Advanced Technologies & Treatments for Diabetes, June 2021
| | - Brooke Narron
- Atlanta Diabetes Associates, Atlanta, Georgia, USA
- Results of this study were presented in abstract form at the 14th International Conference on Advanced Technologies & Treatments for Diabetes, June 2021
| | - Lauren M. Huyett
- Insulet Corporation, Acton, Massachusetts, USA
- Results of this study were presented in abstract form at the 14th International Conference on Advanced Technologies & Treatments for Diabetes, June 2021
| | - Joon Bok Lee
- Insulet Corporation, Acton, Massachusetts, USA
- Results of this study were presented in abstract form at the 14th International Conference on Advanced Technologies & Treatments for Diabetes, June 2021
| | - Jason O'Connor
- Insulet Corporation, Acton, Massachusetts, USA
- Results of this study were presented in abstract form at the 14th International Conference on Advanced Technologies & Treatments for Diabetes, June 2021
| | - Eric Benjamin
- Insulet Corporation, Acton, Massachusetts, USA
- Results of this study were presented in abstract form at the 14th International Conference on Advanced Technologies & Treatments for Diabetes, June 2021
| | - Bonnie Dumais
- Insulet Corporation, Acton, Massachusetts, USA
- Results of this study were presented in abstract form at the 14th International Conference on Advanced Technologies & Treatments for Diabetes, June 2021
| | - Trang T. Ly
- Insulet Corporation, Acton, Massachusetts, USA
- Results of this study were presented in abstract form at the 14th International Conference on Advanced Technologies & Treatments for Diabetes, June 2021
- Address correspondence to: Trang T. Ly, MBBS, FRACP, PhD, Insulet Corporation, 100 Nagog Park, Acton, MA 01720, USA
| |
Collapse
|
13
|
Davey N, McFeely A, Doyle P, Stankard A, Coveney S, Alsubie N, O'Connor J, Conlon B, Monahan P, Byrne P, Britton D, Halpin T, McShane S, Sohail I, Lynch O, Basit M, NiBhuachalla B, Mulroy M, O'Brien H. 103 ORTHOGERIATRIC SERVICES IN THE FACE OF COVID-19. Age Ageing 2021. [PMCID: PMC8690012 DOI: 10.1093/ageing/afab219.103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Background Nationally agreed standards improve the level of care delivered to all older, frail, multi-morbid patients presenting with hip fractures. Dedicated Orthogeriatric services allow for these standards to be achieved in a multi-disciplinary team (MDT) setting. As the COVID-19 pandemic reached our shores, the model of care set out by the Irish Hip Fracture Standards (IHFS) was under threat. Our dedicated Orthopaedic Trauma ward became an acute COVID ward and the Orthogeriatric service was re-deployed to acute medicine for Quarter 2. Methods Using the Irish Hip Fracture Database, local data was analysed and compared with national data from Quarter 1 to 4 (Q1–4) in 2020. Results When comparing local IHFS’s with national figures, ongoing challenges and future goals are highlighted. In 2020, there were 222 hip fracture patients (mean age 81.8 years) in our hospital. Standard 1, time to the ward <4 hours, stands at 71% locally (national average 33%). Standard 2, time to theatre <48 hours, is an ongoing challenge and remains at 66% (national average 75%). Standard 3, pressure ulcer rate, was the same as the national average at 3%. Standards 4, 5 and 6 in our hospital stand at 87% (national averages of 82%, 91% and 85% respectively). In Q1, 56%, or over 1 in every 2 patients with hip fractures, met all of the Irish Hip Fracture Standards in our hospital. In Q2, only 18% of patients met all of the IHFS’s. Q3 saw improvements with 47% of all hip fracture patients achieving all IHFS’s. Q4 showed maintenance with 45% of all patients achieving all IHFS’s. Conclusion These findings highlight the need for a dedicated Orthogeriatric Service and Orthopaedic ward at all times. Going forward with the risk of future waves and the emergence of new variants, every effort should be made to maintain a comprehensive orthogeriatric service to minimise a negative impact on patient care.
Collapse
Affiliation(s)
- N Davey
- Our Lady of Lourdes Hospital Drogheda, Drogheda, Ireland
| | - A McFeely
- Our Lady of Lourdes Hospital Drogheda, Drogheda, Ireland
| | - P Doyle
- Our Lady of Lourdes Hospital Drogheda, Drogheda, Ireland
| | - A Stankard
- Our Lady of Lourdes Hospital Drogheda, Drogheda, Ireland
| | - S Coveney
- Our Lady of Lourdes Hospital Drogheda, Drogheda, Ireland
| | - N Alsubie
- Our Lady of Lourdes Hospital Drogheda, Drogheda, Ireland
| | - J O'Connor
- Our Lady of Lourdes Hospital Drogheda, Drogheda, Ireland
| | - B Conlon
- Our Lady of Lourdes Hospital Drogheda, Drogheda, Ireland
| | - P Monahan
- Our Lady of Lourdes Hospital Drogheda, Drogheda, Ireland
| | - P Byrne
- Our Lady of Lourdes Hospital Drogheda, Drogheda, Ireland
| | - D Britton
- Our Lady of Lourdes Hospital Drogheda, Drogheda, Ireland
| | - T Halpin
- Our Lady of Lourdes Hospital Drogheda, Drogheda, Ireland
| | - S McShane
- Our Lady of Lourdes Hospital Drogheda, Drogheda, Ireland
| | - I Sohail
- Our Lady of Lourdes Hospital Drogheda, Drogheda, Ireland
| | - O Lynch
- Our Lady of Lourdes Hospital Drogheda, Drogheda, Ireland
| | - M Basit
- Our Lady of Lourdes Hospital Drogheda, Drogheda, Ireland
| | - B NiBhuachalla
- Our Lady of Lourdes Hospital Drogheda, Drogheda, Ireland
| | - M Mulroy
- Our Lady of Lourdes Hospital Drogheda, Drogheda, Ireland
| | - H O'Brien
- Our Lady of Lourdes Hospital Drogheda, Drogheda, Ireland
| |
Collapse
|
14
|
Iliff HA, El-Boghdadly K, Ahmad I, Davis J, Harris A, Khan S, Lan-Pak-Kee V, O'Connor J, Powell L, Rees G, Tatla TS. Management of haematoma after thyroid surgery: systematic review and multidisciplinary consensus guidelines from the Difficult Airway Society, the British Association of Endocrine and Thyroid Surgeons and the British Association of Otorhinolaryngology, Head and Neck Surgery. Anaesthesia 2021; 77:82-95. [PMID: 34545943 PMCID: PMC9291554 DOI: 10.1111/anae.15585] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/22/2021] [Indexed: 12/16/2022]
Abstract
Haematoma after thyroid surgery can lead to airway obstruction and death. We therefore developed guidelines to improve the safety of peri‐operative care of patients undergoing thyroid surgery. We conducted a systematic review to inform recommendations, with expert consensus used in the absence of high‐quality evidence, and a Delphi study was used to ratify recommendations. We highlight the importance of multidisciplinary team management and make recommendations in key areas including: monitoring; recognition; post‐thyroid surgery emergency box; management of suspected haematoma following thyroid surgery; cognitive aids; post‐haematoma evacuation care; day‐case thyroid surgery; training; consent and pre‐operative communication; postoperative communication; and institutional policies. The guidelines support a multidisciplinary approach to the management of suspected haematoma following thyroid surgery through oxygenation and evaluation; haematoma evacuation; and tracheal intubation. They have been produced with materials to support implementation. While these guidelines are specific to thyroid surgery, the principles may apply to other forms of neck surgery. These guidelines and recommendations provided are the first in this area and it is hoped they will support multidisciplinary team working, improving care and outcomes for patients having thyroid surgery.
Collapse
Affiliation(s)
- H A Iliff
- Department of Anaesthesia, Cwm Taf Morgannwg University Health Board, Merthyr, UK.,Health Education and Improvement Wales, Cardiff, UK
| | - K El-Boghdadly
- Department of Anaesthesia and Peri-operative Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK.,King's College London, London, UK
| | - I Ahmad
- Department of Anaesthesia and Peri-operative Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK.,King's College London, London, UK
| | - J Davis
- Department of Otolaryngology Head and Neck Surgery, Medway NHS Foundation Trust, Gillingham, UK
| | - A Harris
- Patient Representative, London, UK
| | - S Khan
- Department of Endocrine Surgery, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | - V Lan-Pak-Kee
- Department of Anaesthesia, Barts Health NHS Trust, London, UK
| | - J O'Connor
- Department of Otolaryngology Head and Neck Surgery, London North West University Healthcare NHS Trust, London, UK
| | - L Powell
- Department of Anaesthesia, Cwm Taf Morgannwg University Health Board, Merthyr, UK.,Health Education and Improvement Wales, Cardiff, UK
| | - G Rees
- Department of Anaesthesia, Cwm Taf Morgannwg University Health Board, Merthyr, UK
| | - T S Tatla
- Department of Otolaryngology Head and Neck Surgery, London North West University Healthcare NHS Trust, London, UK
| |
Collapse
|
15
|
Moran J, Tuten T, Anderson C, Dunn K, O'Connor J, Saxton J, Buescher C, Miller K, Nagid E, Ortiz L, Simonton L, Holzwart KR. Range Extension of Spotted Bullhead, Ameiurus serracanthus, Family Ictaluridae, in Peninsular Florida. SOUTHEAST NAT 2021. [DOI: 10.1656/058.020.0311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
16
|
Forlenza GP, Buckingham BA, Brown SA, Bode BW, Levy CJ, Criego AB, Wadwa RP, Cobry EC, Slover RJ, Messer LH, Berget C, McCoy S, Ekhlaspour L, Kingman RS, Voelmle MK, Boyd J, O'Malley G, Grieme A, Kivilaid K, Kleve K, Dumais B, Vienneau T, Huyett LM, Lee JB, O'Connor J, Benjamin E, Ly TT. First Outpatient Evaluation of a Tubeless Automated Insulin Delivery System with Customizable Glucose Targets in Children and Adults with Type 1 Diabetes. Diabetes Technol Ther 2021; 23:410-424. [PMID: 33325779 PMCID: PMC8215410 DOI: 10.1089/dia.2020.0546] [Citation(s) in RCA: 30] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Background: The objective of this study was to assess the safety and effectiveness of the first commercial configuration of a tubeless automated insulin delivery system, Omnipod® 5, in children (6-13.9 years) and adults (14-70 years) with type 1 diabetes (T1D) in an outpatient setting. Materials and Methods: This was a single-arm, multicenter, prospective clinical study. Data were collected over a 14-day standard therapy (ST) phase followed by a 14-day hybrid closed-loop (HCL) phase, where participants (n = 36) spent 72 h at each of three prespecified glucose targets (130, 140, and 150 mg/dL, 9 days total) then 5 days with free choice of glucose targets (110-150 mg/dL) using the Omnipod 5. Remote safety monitoring alerts were enabled during the HCL phase. Primary endpoints were difference in time in range (TIR) (70-180 mg/dL) between ST and HCL phases and proportion of participants reporting serious device-related adverse events. Results: Mean TIR was significantly higher among children in the free-choice period overall (64.9% ± 12.2%, P < 0.01) and when using a 110 mg/dL target (71.2% ± 10.2%, P < 0.01), a 130 mg/dL target (61.5% ± 7.7%, P < 0.01), and a 140 mg/dL target (64.8% ± 11.6%, P < 0.01), and among adults using a 130 mg/dL target (75.1% ± 11.6%, P < 0.05), compared to the ST phase (children: 51.0% ± 13.3% and adults: 65.6% ± 15.7%). There were no serious device-related adverse events reported during the HCL phase, nor were there episodes of severe hypoglycemia or diabetic ketoacidosis. Conclusion: The Omnipod 5 System was safe and effective when used at glucose targets from 110 to 150 mg/dL for 14 days at home in children and adults with T1D.
Collapse
Affiliation(s)
- Gregory P. Forlenza
- Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, Colorado, USA
| | - Bruce A. Buckingham
- Department of Pediatrics, Division of Pediatric Endocrinology, Stanford University, Stanford, California, USA
| | - Sue A. Brown
- Division of Endocrinology and Medicine, University of Virginia, Charlottesville, Virginia, USA
| | | | - Carol J. Levy
- Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Amy B. Criego
- Department of Pediatric Endocrinology, Park Nicollet Clinic, International Diabetes Center at Park Nicollet, Minneapolis, Minnesota, USA
| | - R. Paul Wadwa
- Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, Colorado, USA
| | - Erin C. Cobry
- Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, Colorado, USA
| | - Robert J. Slover
- Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, Colorado, USA
| | - Laurel H. Messer
- Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, Colorado, USA
| | - Cari Berget
- Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, Colorado, USA
| | - Susan McCoy
- Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, Colorado, USA
| | - Laya Ekhlaspour
- Department of Pediatrics, Division of Pediatric Endocrinology, Stanford University, Stanford, California, USA
| | - Ryan S. Kingman
- Department of Pediatrics, Division of Pediatric Endocrinology, Stanford University, Stanford, California, USA
| | - Mary K. Voelmle
- Division of Endocrinology and Medicine, University of Virginia, Charlottesville, Virginia, USA
| | | | - Grenye O'Malley
- Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Aimee Grieme
- Department of Pediatric Endocrinology, Park Nicollet Clinic, International Diabetes Center at Park Nicollet, Minneapolis, Minnesota, USA
| | | | | | | | | | | | | | | | | | - Trang T. Ly
- Insulet Corporation, Acton, Massachusetts, USA
- Address correspondence to: Trang T. Ly, MBBS, FRACP, PhD, Insulet Corporation, 100 Nagog Park, Acton, MA 01720, USA
| |
Collapse
|
17
|
Murray RM, Mondelli V, Stilo SA, Trotta A, Sideli L, Ajnakina O, Ferraro L, Vassos E, Iyegbe C, Schoeler T, Bhattacharyya S, Marques TR, Dazzan P, Lopez-Morinigo J, Colizzi M, O'Connor J, Falcone MA, Quattrone D, Rodriguez V, Tripoli G, La Barbera D, La Cascia C, Alameda L, Trotta G, Morgan C, Gaughran F, David A, Di Forti M. The influence of risk factors on the onset and outcome of psychosis: What we learned from the GAP study. Schizophr Res 2020; 225:63-68. [PMID: 32037203 DOI: 10.1016/j.schres.2020.01.011] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/27/2019] [Revised: 01/06/2020] [Accepted: 01/09/2020] [Indexed: 01/05/2023]
Abstract
The GAP multidisciplinary study carried out in South London, recruited 410 first episode of psychosis patients and 370 controls; the aim was to elucidate the multiple genetic and environmental factors influencing the onset and outcome of psychosis. The study demonstrated the risk increasing effect of adversity in childhood (especially parental loss, abuse, and bullying) on onset of psychosis especially positive symptoms. Adverse life events more proximal to onset, being from an ethnic minority, and cannabis use also played important roles; indeed, one quarter of new cases of psychosis could be attributed to use of high potency cannabis. The "jumping to conclusions" bias appeared to mediate the effect of lower IQ on vulnerability to psychosis. We confirmed that environmental factors operate on the background of polygenic risk, and that genetic and environment act together to push individuals over the threshold for manifesting the clinical disorder. The study demonstrated how biological pathways involved in the stress response (HPA axis and immune system) provide important mechanisms linking social risk factors to the development of psychotic symptoms. Further evidence implicating an immune/inflammatory component to psychosis came from our finding of complement dysregulation in FEP. Patients also showed an upregulation of the antimicrobial alpha-defensins, as well as differences in expression patterns of genes involved in NF-κB signaling and Cytokine Production. Being of African origin not only increased risk of onset but also of a more difficult course of illness. The malign effect of childhood adversity predicted a poorer outcome as did continued use of high potency cannabis.
Collapse
Affiliation(s)
- R M Murray
- Institute of Psychiatry, Psychology and Neuroscience, Department of Psychosis Studies, King's College London, London, UK; Department of Experimental Biomedicine and Clinical Neuroscience, University of Palermo, Palermo, Italy.
| | - V Mondelli
- Institute of Psychiatry, Psychology and Neuroscience, Department of Psychosis Studies, King's College London, London, UK
| | - S A Stilo
- Institute of Psychiatry, Psychology and Neuroscience, Department of Psychosis Studies, King's College London, London, UK; Division of Psychology and Language Sciences, University College London, London, UK
| | - A Trotta
- Institute of Psychiatry, Psychology and Neuroscience, Department of Psychosis Studies, King's College London, London, UK
| | - L Sideli
- Institute of Psychiatry, Psychology and Neuroscience, Department of Psychosis Studies, King's College London, London, UK; Department of Experimental Biomedicine and Clinical Neuroscience, University of Palermo, Palermo, Italy
| | - O Ajnakina
- Institute of Psychiatry, Psychology and Neuroscience, Department of Psychosis Studies, King's College London, London, UK
| | - L Ferraro
- Department of Experimental Biomedicine and Clinical Neuroscience, University of Palermo, Palermo, Italy
| | - E Vassos
- Institute of Psychiatry, Psychology and Neuroscience, Department of Psychosis Studies, King's College London, London, UK
| | - C Iyegbe
- Institute of Psychiatry, Psychology and Neuroscience, Department of Psychosis Studies, King's College London, London, UK
| | - T Schoeler
- Institute of Psychiatry, Psychology and Neuroscience, Department of Psychosis Studies, King's College London, London, UK; Department of Psychiatry, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - S Bhattacharyya
- Institute of Psychiatry, Psychology and Neuroscience, Department of Psychosis Studies, King's College London, London, UK
| | - T R Marques
- Institute of Psychiatry, Psychology and Neuroscience, Department of Psychosis Studies, King's College London, London, UK
| | - P Dazzan
- Institute of Psychiatry, Psychology and Neuroscience, Department of Psychosis Studies, King's College London, London, UK
| | - J Lopez-Morinigo
- Institute of Psychiatry, Psychology and Neuroscience, Department of Psychosis Studies, King's College London, London, UK; Department of Psychiatry, Universidad Autónoma de Madrid, Madrid, Spain
| | - M Colizzi
- Institute of Psychiatry, Psychology and Neuroscience, Department of Psychosis Studies, King's College London, London, UK
| | - J O'Connor
- Institute of Psychiatry, Psychology and Neuroscience, Department of Psychosis Studies, King's College London, London, UK; Department of Neuropsychology, Royal Free London NHS Foundation Trust, Royal Free Hospital, London, UK
| | - M A Falcone
- Institute of Psychiatry, Psychology and Neuroscience, Department of Psychosis Studies, King's College London, London, UK
| | - D Quattrone
- Institute of Psychiatry, Psychology and Neuroscience, Department of Psychosis Studies, King's College London, London, UK
| | - V Rodriguez
- Institute of Psychiatry, Psychology and Neuroscience, Department of Psychosis Studies, King's College London, London, UK
| | - G Tripoli
- Institute of Psychiatry, Psychology and Neuroscience, Department of Psychosis Studies, King's College London, London, UK; Department of Experimental Biomedicine and Clinical Neuroscience, University of Palermo, Palermo, Italy
| | - D La Barbera
- Department of Experimental Biomedicine and Clinical Neuroscience, University of Palermo, Palermo, Italy
| | - C La Cascia
- Department of Experimental Biomedicine and Clinical Neuroscience, University of Palermo, Palermo, Italy
| | - L Alameda
- Institute of Psychiatry, Psychology and Neuroscience, Department of Psychosis Studies, King's College London, London, UK
| | - G Trotta
- Institute of Psychiatry, Psychology and Neuroscience, Department of Psychosis Studies, King's College London, London, UK; Department of Medicine and Surgery, University of Milano Bicocca, Monza, Italy
| | - C Morgan
- Institute of Psychiatry, Psychology and Neuroscience, Department of Psychosis Studies, King's College London, London, UK
| | - F Gaughran
- Institute of Psychiatry, Psychology and Neuroscience, Department of Psychosis Studies, King's College London, London, UK
| | - A David
- Institute of Psychiatry, Psychology and Neuroscience, Department of Psychosis Studies, King's College London, London, UK; Institute of Mental Health, University College London, London, UK
| | - M Di Forti
- Institute of Psychiatry, Psychology and Neuroscience, Department of Psychosis Studies, King's College London, London, UK; Department of Experimental Biomedicine and Clinical Neuroscience, University of Palermo, Palermo, Italy
| |
Collapse
|
18
|
Adamson P, Anghel I, Aurisano A, Barr G, Blake A, Cao SV, Carroll TJ, Castromonte CM, Chen R, Childress S, Coelho JAB, De Rijck S, Evans JJ, Feldman GJ, Flanagan W, Gabrielyan M, Germani S, Gomes RA, Gouffon P, Graf N, Grzelak K, Habig A, Hahn SR, Hartnell J, Hatcher R, Holin A, Huang J, Koerner LW, Kordosky M, Kreymer A, Lang K, Lucas P, Mann WA, Marshak ML, Mayer N, Mehdiyev R, Meier JR, Miller WH, Mills G, Naples D, Nelson JK, Nichol RJ, O'Connor J, Pahlka RB, Pavlović Ž, Pawloski G, Perch A, Pfützner MM, Phan DD, Plunkett RK, Poonthottathil N, Qiu X, Radovic A, Sail P, Sanchez MC, Schneps J, Schreckenberger A, Sharma R, Sousa A, Tagg N, Thomas J, Thomson MA, Timmons A, Todd J, Tognini SC, Toner R, Torretta D, Vahle P, Weber A, Whitehead LH, Wojcicki SG. Precision Constraints for Three-Flavor Neutrino Oscillations from the Full MINOS+ and MINOS Dataset. Phys Rev Lett 2020; 125:131802. [PMID: 33034464 DOI: 10.1103/physrevlett.125.131802] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Accepted: 08/19/2020] [Indexed: 06/11/2023]
Abstract
We report the final measurement of the neutrino oscillation parameters Δm_{32}^{2} and sin^{2}θ_{23} using all data from the MINOS and MINOS+ experiments. These data were collected using a total exposure of 23.76×10^{20} protons on target producing ν_{μ} and ν[over ¯]_{μ} beams and 60.75 kt yr exposure to atmospheric neutrinos. The measurement of the disappearance of ν_{μ} and the appearance of ν_{e} events between the Near and Far detectors yields |Δm_{32}^{2}|=2.40_{-0.09}^{+0.08}(2.45_{-0.08}^{+0.07})×10^{-3} eV^{2} and sin^{2}θ_{23}=0.43_{-0.04}^{+0.20}(0.42_{-0.03}^{+0.07}) at 68% C.L. for normal (inverted) hierarchy.
Collapse
Affiliation(s)
- P Adamson
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - I Anghel
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011 USA
| | - A Aurisano
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - G Barr
- Subdepartment of Particle Physics, University of Oxford, Oxford OX1 3RH, United Kingdom
| | - A Blake
- Cavendish Laboratory, University of Cambridge, Cambridge CB3 0HE, United Kingdom
- Lancaster University, Lancaster, LA1 4YB, United Kingdom
| | - S V Cao
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - T J Carroll
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - C M Castromonte
- Instituto de Física, Universidade Federal de Goiás, 74690-900, Goiánia, GO, Brazil
| | - R Chen
- Department of Physics and Astronomy, University of Manchester, Manchester M13 9PL, United Kingdom
| | - S Childress
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - J A B Coelho
- Physics Department, Tufts University, Medford, Massachusetts 02155, USA
| | - S De Rijck
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - J J Evans
- Department of Physics and Astronomy, University of Manchester, Manchester M13 9PL, United Kingdom
| | - G J Feldman
- Department of Physics, Harvard University, Cambridge, Massachusetts 02138, USA
| | - W Flanagan
- Department of Physics, University of Dallas, Irving, Texas 75062, USA
| | - M Gabrielyan
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - S Germani
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - R A Gomes
- Instituto de Física, Universidade Federal de Goiás, 74690-900, Goiánia, GO, Brazil
| | - P Gouffon
- Instituto de Física, Universidade de São Paulo, CP 66318, 05315-970, São Paulo, SP, Brazil
| | - N Graf
- Department of Physics and Astronomy, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA
| | - K Grzelak
- Department of Physics, University of Warsaw, PL-02-093 Warsaw, Poland
| | - A Habig
- Department of Physics, University of Minnesota Duluth, Duluth, Minnesota 55812, USA
| | - S R Hahn
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - J Hartnell
- Department of Physics and Astronomy, University of Sussex, Falmer, Brighton BN1 9QH, United Kingdom
| | - R Hatcher
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - A Holin
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - J Huang
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - L W Koerner
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - M Kordosky
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
| | - A Kreymer
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - K Lang
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - P Lucas
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - W A Mann
- Physics Department, Tufts University, Medford, Massachusetts 02155, USA
| | - M L Marshak
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - N Mayer
- Physics Department, Tufts University, Medford, Massachusetts 02155, USA
| | - R Mehdiyev
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - J R Meier
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - W H Miller
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - G Mills
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - D Naples
- Department of Physics and Astronomy, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA
| | - J K Nelson
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
| | - R J Nichol
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - J O'Connor
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - R B Pahlka
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - Ž Pavlović
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - G Pawloski
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - A Perch
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - M M Pfützner
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - D D Phan
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - R K Plunkett
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - N Poonthottathil
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - X Qiu
- Department of Physics, Stanford University, Stanford, California 94305, USA
| | - A Radovic
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
| | - P Sail
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - M C Sanchez
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011 USA
| | - J Schneps
- Physics Department, Tufts University, Medford, Massachusetts 02155, USA
| | - A Schreckenberger
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - R Sharma
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - A Sousa
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - N Tagg
- Otterbein University, Westerville, Ohio 43081, USA
| | - J Thomas
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - M A Thomson
- Cavendish Laboratory, University of Cambridge, Cambridge CB3 0HE, United Kingdom
| | - A Timmons
- Department of Physics and Astronomy, University of Manchester, Manchester M13 9PL, United Kingdom
| | - J Todd
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - S C Tognini
- Instituto de Física, Universidade Federal de Goiás, 74690-900, Goiánia, GO, Brazil
| | - R Toner
- Department of Physics, Harvard University, Cambridge, Massachusetts 02138, USA
| | - D Torretta
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - P Vahle
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
| | - A Weber
- Subdepartment of Particle Physics, University of Oxford, Oxford OX1 3RH, United Kingdom
- Rutherford Appleton Laboratory, Science and Technology Facilities Council, Didcot, OX11 0QX, United Kingdom
| | - L H Whitehead
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - S G Wojcicki
- Department of Physics, Stanford University, Stanford, California 94305, USA
| |
Collapse
|
19
|
Adamson P, An FP, Anghel I, Aurisano A, Balantekin AB, Band HR, Barr G, Bishai M, Blake A, Blyth S, Cao GF, Cao J, Cao SV, Carroll TJ, Castromonte CM, Chang JF, Chang Y, Chen HS, Chen R, Chen SM, Chen Y, Chen YX, Cheng J, Cheng ZK, Cherwinka JJ, Childress S, Chu MC, Chukanov A, Coelho JAB, Cummings JP, Dash N, De Rijck S, Deng FS, Ding YY, Diwan MV, Dohnal T, Dolzhikov D, Dove J, Dvořák M, Dwyer DA, Evans JJ, Feldman GJ, Flanagan W, Gabrielyan M, Gallo JP, Germani S, Gomes RA, Gonchar M, Gong GH, Gong H, Gouffon P, Graf N, Grzelak K, Gu WQ, Guo JY, Guo L, Guo XH, Guo YH, Guo Z, Habig A, Hackenburg RW, Hahn SR, Hans S, Hartnell J, Hatcher R, He M, Heeger KM, Heng YK, Higuera A, Holin A, Hor YK, Hsiung YB, Hu BZ, Hu JR, Hu T, Hu ZJ, Huang HX, Huang J, Huang XT, Huang YB, Huber P, Jaffe DE, Jen KL, Ji XL, Ji XP, Johnson RA, Jones D, Kang L, Kettell SH, Koerner LW, Kohn S, Kordosky M, Kramer M, Kreymer A, Lang K, Langford TJ, Lee J, Lee JHC, Lei RT, Leitner R, Leung JKC, Li F, Li HL, Li JJ, Li QJ, Li S, Li SC, Li SJ, Li WD, Li XN, Li XQ, Li YF, Li ZB, Liang H, Lin CJ, Lin GL, Lin S, Ling JJ, Link JM, Littenberg L, Littlejohn BR, Liu JC, Liu JL, Liu Y, Liu YH, Lu C, Lu HQ, Lu JS, Lucas P, Luk KB, Ma XB, Ma XY, Ma YQ, Mann WA, Marshak ML, Marshall C, Martinez Caicedo DA, Mayer N, McDonald KT, McKeown RD, Mehdiyev R, Meier JR, Meng Y, Miller WH, Mills G, Mora Lepin L, Naples D, Napolitano J, Naumov D, Naumova E, Nelson JK, Nichol RJ, O'Connor J, Ochoa-Ricoux JP, Olshevskiy A, Pahlka RB, Pan HR, Park J, Patton S, Pavlović Ž, Pawloski G, Peng JC, Perch A, Pfützner MM, Phan DD, Plunkett RK, Poonthottathil N, Pun CSJ, Qi FZ, Qi M, Qian X, Qiu X, Radovic A, Raper N, Ren J, Reveco CM, Rosero R, Roskovec B, Ruan XC, Sail P, Sanchez MC, Schneps J, Schreckenberger A, Shaheed N, Sharma R, Sousa A, Steiner H, Sun JL, Tagg N, Thomas J, Thomson MA, Timmons A, Tmej T, Todd J, Tognini SC, Toner R, Torretta D, Treskov K, Tse WH, Tull CE, Vahle P, Viren B, Vorobel V, Wang CH, Wang J, Wang M, Wang NY, Wang RG, Wang W, Wang W, Wang X, Wang Y, Wang YF, Wang Z, Wang Z, Wang ZM, Weber A, Wei HY, Wei LH, Wen LJ, Whisnant K, White C, Whitehead LH, Wojcicki SG, Wong HLH, Wong SCF, Worcester E, Wu DR, Wu FL, Wu Q, Wu WJ, Xia DM, Xie ZQ, Xing ZZ, Xu JL, Xu T, Xue T, Yang CG, Yang L, Yang YZ, Yao HF, Ye M, Yeh M, Young BL, Yu HZ, Yu ZY, Yue BB, Zeng S, Zeng Y, Zhan L, Zhang C, Zhang FY, Zhang HH, Zhang JW, Zhang QM, Zhang XT, Zhang YM, Zhang YX, Zhang YY, Zhang ZJ, Zhang ZP, Zhang ZY, Zhao J, Zhou L, Zhuang HL. Improved Constraints on Sterile Neutrino Mixing from Disappearance Searches in the MINOS, MINOS+, Daya Bay, and Bugey-3 Experiments. Phys Rev Lett 2020; 125:071801. [PMID: 32857527 DOI: 10.1103/physrevlett.125.071801] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/04/2020] [Revised: 06/13/2020] [Accepted: 06/15/2020] [Indexed: 06/11/2023]
Abstract
Searches for electron antineutrino, muon neutrino, and muon antineutrino disappearance driven by sterile neutrino mixing have been carried out by the Daya Bay and MINOS+ collaborations. This Letter presents the combined results of these searches, along with exclusion results from the Bugey-3 reactor experiment, framed in a minimally extended four-neutrino scenario. Significantly improved constraints on the θ_{μe} mixing angle are derived that constitute the most constraining limits to date over five orders of magnitude in the mass-squared splitting Δm_{41}^{2}, excluding the 90% C.L. sterile-neutrino parameter space allowed by the LSND and MiniBooNE observations at 90% CL_{s} for Δm_{41}^{2}<13 eV^{2}. Furthermore, the LSND and MiniBooNE 99% C.L. allowed regions are excluded at 99% CL_{s} for Δm_{41}^{2}<1.6 eV^{2}.
Collapse
Affiliation(s)
- P Adamson
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - F P An
- Institute of Modern Physics, East China University of Science and Technology, Shanghai
| | - I Anghel
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011 USA
| | - A Aurisano
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - A B Balantekin
- Physics Department, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - H R Band
- Wright Laboratory and Department of Physics, Yale University, New Haven, Connecticut 06520, USA
| | - G Barr
- Subdepartment of Particle Physics, University of Oxford, Oxford OX1 3RH, United Kingdom
| | - M Bishai
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - A Blake
- Cavendish Laboratory, University of Cambridge, Cambridge CB3 0HE, United Kingdom
- Lancaster University, Lancaster, LA1 4YB, United Kingdom
| | - S Blyth
- Department of Physics, National Taiwan University, Taipei
| | - G F Cao
- Institute of High Energy Physics, Beijing
| | - J Cao
- Institute of High Energy Physics, Beijing
| | - S V Cao
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - T J Carroll
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - C M Castromonte
- Instituto de Física, Universidade Federal de Goiás, 74690-900, Goiánia, Goias, Brazil
| | - J F Chang
- Institute of High Energy Physics, Beijing
| | - Y Chang
- National United University, Miao-Li
| | - H S Chen
- Institute of High Energy Physics, Beijing
| | - R Chen
- Department of Physics and Astronomy, University of Manchester, Manchester M13 9PL, United Kingdom
| | - S M Chen
- Department of Engineering Physics, Tsinghua University, Beijing
| | - Y Chen
- Shenzhen University, Shenzhen
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - Y X Chen
- North China Electric Power University, Beijing
| | - J Cheng
- Institute of High Energy Physics, Beijing
| | - Z K Cheng
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - J J Cherwinka
- Physics Department, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - S Childress
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - M C Chu
- Chinese University of Hong Kong, Hong Kong
| | - A Chukanov
- Joint Institute for Nuclear Research, Dubna, Moscow Region, Russia
| | - J A B Coelho
- Physics Department, Tufts University, Medford, Massachusetts 02155, USA
| | | | - N Dash
- Institute of High Energy Physics, Beijing
| | - S De Rijck
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - F S Deng
- University of Science and Technology of China, Hefei
| | - Y Y Ding
- Institute of High Energy Physics, Beijing
| | - M V Diwan
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - T Dohnal
- Charles University, Faculty of Mathematics and Physics, Prague, Czech Republic
| | - D Dolzhikov
- Joint Institute for Nuclear Research, Dubna, Moscow Region, Russia
| | - J Dove
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA
| | - M Dvořák
- Institute of High Energy Physics, Beijing
| | - D A Dwyer
- Lawrence Berkeley National Laboratory, Berkeley, California, 94720 USA
| | - J J Evans
- Department of Physics and Astronomy, University of Manchester, Manchester M13 9PL, United Kingdom
| | - G J Feldman
- Department of Physics, Harvard University, Cambridge, Massachusetts 02138, USA
| | - W Flanagan
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
- Department of Physics, University of Dallas, Irving, Texas 75062, USA
| | - M Gabrielyan
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - J P Gallo
- Department of Physics, Illinois Institute of Technology, Chicago, Illinois 60616, USA
| | - S Germani
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - R A Gomes
- Instituto de Física, Universidade Federal de Goiás, 74690-900, Goiánia, Goias, Brazil
| | - M Gonchar
- Joint Institute for Nuclear Research, Dubna, Moscow Region, Russia
| | - G H Gong
- Department of Engineering Physics, Tsinghua University, Beijing
| | - H Gong
- Department of Engineering Physics, Tsinghua University, Beijing
| | - P Gouffon
- Instituto de Física, Universidade de São Paulo, CP 66318, 05315-970, São Paulo, Sao Paulo, Brazil
| | - N Graf
- Department of Physics and Astronomy, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA
| | - K Grzelak
- Department of Physics, University of Warsaw, PL-02-093 Warsaw, Poland
| | - W Q Gu
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - J Y Guo
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - L Guo
- Department of Engineering Physics, Tsinghua University, Beijing
| | - X H Guo
- Beijing Normal University, Beijing
| | - Y H Guo
- Department of Nuclear Science and Technology, School of Energy and Power Engineering, Xi'an Jiaotong University, Xi'an
| | - Z Guo
- Department of Engineering Physics, Tsinghua University, Beijing
| | - A Habig
- Department of Physics, University of Minnesota Duluth, Duluth, Minnesota 55812, USA
| | - R W Hackenburg
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - S R Hahn
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - S Hans
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - J Hartnell
- Department of Physics and Astronomy, University of Sussex, Falmer, Brighton BN1 9QH, United Kingdom
| | - R Hatcher
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - M He
- Institute of High Energy Physics, Beijing
| | - K M Heeger
- Wright Laboratory and Department of Physics, Yale University, New Haven, Connecticut 06520, USA
| | - Y K Heng
- Institute of High Energy Physics, Beijing
| | - A Higuera
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - A Holin
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - Y K Hor
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - Y B Hsiung
- Department of Physics, National Taiwan University, Taipei
| | - B Z Hu
- Department of Physics, National Taiwan University, Taipei
| | - J R Hu
- Institute of High Energy Physics, Beijing
| | - T Hu
- Institute of High Energy Physics, Beijing
| | - Z J Hu
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - H X Huang
- China Institute of Atomic Energy, Beijing
| | - J Huang
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | | | - Y B Huang
- Institute of High Energy Physics, Beijing
| | - P Huber
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia 24061, USA
| | - D E Jaffe
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - K L Jen
- Institute of Physics, National Chiao-Tung University, Hsinchu
| | - X L Ji
- Institute of High Energy Physics, Beijing
| | - X P Ji
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - R A Johnson
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - D Jones
- Department of Physics, College of Science and Technology, Temple University, Philadelphia, Pennsylvania 19122, USA
| | - L Kang
- Dongguan University of Technology, Dongguan
| | - S H Kettell
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - L W Koerner
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - S Kohn
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - M Kordosky
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
| | - M Kramer
- Lawrence Berkeley National Laboratory, Berkeley, California, 94720 USA
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - A Kreymer
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - K Lang
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - T J Langford
- Wright Laboratory and Department of Physics, Yale University, New Haven, Connecticut 06520, USA
| | - J Lee
- Lawrence Berkeley National Laboratory, Berkeley, California, 94720 USA
| | - J H C Lee
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong
| | - R T Lei
- Dongguan University of Technology, Dongguan
| | - R Leitner
- Charles University, Faculty of Mathematics and Physics, Prague, Czech Republic
| | - J K C Leung
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong
| | - F Li
- Institute of High Energy Physics, Beijing
| | - H L Li
- Institute of High Energy Physics, Beijing
| | - J J Li
- Department of Engineering Physics, Tsinghua University, Beijing
| | - Q J Li
- Institute of High Energy Physics, Beijing
| | - S Li
- Dongguan University of Technology, Dongguan
| | - S C Li
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia 24061, USA
| | - S J Li
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - W D Li
- Institute of High Energy Physics, Beijing
| | - X N Li
- Institute of High Energy Physics, Beijing
| | - X Q Li
- School of Physics, Nankai University, Tianjin
| | - Y F Li
- Institute of High Energy Physics, Beijing
| | - Z B Li
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - H Liang
- University of Science and Technology of China, Hefei
| | - C J Lin
- Lawrence Berkeley National Laboratory, Berkeley, California, 94720 USA
| | - G L Lin
- Institute of Physics, National Chiao-Tung University, Hsinchu
| | - S Lin
- Dongguan University of Technology, Dongguan
| | - J J Ling
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - J M Link
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia 24061, USA
| | - L Littenberg
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - B R Littlejohn
- Department of Physics, Illinois Institute of Technology, Chicago, Illinois 60616, USA
| | - J C Liu
- Institute of High Energy Physics, Beijing
| | - J L Liu
- Department of Physics and Astronomy, Shanghai Jiao Tong University, Shanghai Laboratory for Particle Physics and Cosmology, Shanghai
| | - Y Liu
- Shandong University, Jinan
| | | | - C Lu
- Joseph Henry Laboratories, Princeton University, Princeton, New Jersey 08544, USA
| | - H Q Lu
- Institute of High Energy Physics, Beijing
| | - J S Lu
- Institute of High Energy Physics, Beijing
| | - P Lucas
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - K B Luk
- Lawrence Berkeley National Laboratory, Berkeley, California, 94720 USA
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - X B Ma
- North China Electric Power University, Beijing
| | - X Y Ma
- Institute of High Energy Physics, Beijing
| | - Y Q Ma
- Institute of High Energy Physics, Beijing
| | - W A Mann
- Physics Department, Tufts University, Medford, Massachusetts 02155, USA
| | - M L Marshak
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - C Marshall
- Lawrence Berkeley National Laboratory, Berkeley, California, 94720 USA
| | - D A Martinez Caicedo
- Department of Physics, Illinois Institute of Technology, Chicago, Illinois 60616, USA
| | - N Mayer
- Physics Department, Tufts University, Medford, Massachusetts 02155, USA
| | - K T McDonald
- Joseph Henry Laboratories, Princeton University, Princeton, New Jersey 08544, USA
| | - R D McKeown
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
- Lauritsen Laboratory, California Institute of Technology, Pasadena, California 91125, USA
| | - R Mehdiyev
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - J R Meier
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - Y Meng
- Department of Physics and Astronomy, Shanghai Jiao Tong University, Shanghai Laboratory for Particle Physics and Cosmology, Shanghai
| | - W H Miller
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - G Mills
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - L Mora Lepin
- Instituto de Física, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - D Naples
- Department of Physics and Astronomy, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA
| | - J Napolitano
- Department of Physics, College of Science and Technology, Temple University, Philadelphia, Pennsylvania 19122, USA
| | - D Naumov
- Joint Institute for Nuclear Research, Dubna, Moscow Region, Russia
| | - E Naumova
- Joint Institute for Nuclear Research, Dubna, Moscow Region, Russia
| | - J K Nelson
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
| | - R J Nichol
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - J O'Connor
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - J P Ochoa-Ricoux
- Department of Physics and Astronomy, University of California, Irvine, California 92697, USA
| | - A Olshevskiy
- Joint Institute for Nuclear Research, Dubna, Moscow Region, Russia
| | - R B Pahlka
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - H-R Pan
- Department of Physics, National Taiwan University, Taipei
| | - J Park
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia 24061, USA
| | - S Patton
- Lawrence Berkeley National Laboratory, Berkeley, California, 94720 USA
| | - Ž Pavlović
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - G Pawloski
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - J C Peng
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA
| | - A Perch
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - M M Pfützner
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - D D Phan
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - R K Plunkett
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - N Poonthottathil
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - C S J Pun
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong
| | - F Z Qi
- Institute of High Energy Physics, Beijing
| | - M Qi
- Nanjing University, Nanjing
| | - X Qian
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - X Qiu
- Department of Physics, Stanford University, Stanford, California 94305, USA
| | - A Radovic
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
| | - N Raper
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - J Ren
- China Institute of Atomic Energy, Beijing
| | - C Morales Reveco
- Instituto de Física, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - R Rosero
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - B Roskovec
- Department of Physics and Astronomy, University of California, Irvine, California 92697, USA
| | - X C Ruan
- China Institute of Atomic Energy, Beijing
| | - P Sail
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - M C Sanchez
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011 USA
| | - J Schneps
- Physics Department, Tufts University, Medford, Massachusetts 02155, USA
| | - A Schreckenberger
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | | | - R Sharma
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - A Sousa
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - H Steiner
- Lawrence Berkeley National Laboratory, Berkeley, California, 94720 USA
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - J L Sun
- China General Nuclear Power Group, Shenzhen
| | - N Tagg
- Otterbein University, Westerville, Ohio 43081, USA
| | - J Thomas
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - M A Thomson
- Cavendish Laboratory, University of Cambridge, Cambridge CB3 0HE, United Kingdom
| | - A Timmons
- Department of Physics and Astronomy, University of Manchester, Manchester M13 9PL, United Kingdom
| | - T Tmej
- Charles University, Faculty of Mathematics and Physics, Prague, Czech Republic
| | - J Todd
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - S C Tognini
- Instituto de Física, Universidade Federal de Goiás, 74690-900, Goiánia, Goias, Brazil
| | - R Toner
- Department of Physics, Harvard University, Cambridge, Massachusetts 02138, USA
| | - D Torretta
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - K Treskov
- Joint Institute for Nuclear Research, Dubna, Moscow Region, Russia
| | - W-H Tse
- Chinese University of Hong Kong, Hong Kong
| | - C E Tull
- Lawrence Berkeley National Laboratory, Berkeley, California, 94720 USA
| | - P Vahle
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
| | - B Viren
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - V Vorobel
- Charles University, Faculty of Mathematics and Physics, Prague, Czech Republic
| | - C H Wang
- National United University, Miao-Li
| | - J Wang
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - M Wang
- Shandong University, Jinan
| | - N Y Wang
- Beijing Normal University, Beijing
| | - R G Wang
- Institute of High Energy Physics, Beijing
| | - W Wang
- Sun Yat-Sen (Zhongshan) University, Guangzhou
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
| | - W Wang
- Nanjing University, Nanjing
| | - X Wang
- College of Electronic Science and Engineering, National University of Defense Technology, Changsha
| | - Y Wang
- Nanjing University, Nanjing
| | - Y F Wang
- Institute of High Energy Physics, Beijing
| | - Z Wang
- Institute of High Energy Physics, Beijing
| | - Z Wang
- Department of Engineering Physics, Tsinghua University, Beijing
| | - Z M Wang
- Institute of High Energy Physics, Beijing
| | - A Weber
- Subdepartment of Particle Physics, University of Oxford, Oxford OX1 3RH, United Kingdom
- Rutherford Appleton Laboratory, Science and Technology Facilities Council, Didcot, OX11 0QX, United Kingdom
| | - H Y Wei
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - L H Wei
- Institute of High Energy Physics, Beijing
| | - L J Wen
- Institute of High Energy Physics, Beijing
| | - K Whisnant
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011 USA
| | - C White
- Department of Physics, Illinois Institute of Technology, Chicago, Illinois 60616, USA
| | - L H Whitehead
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - S G Wojcicki
- Department of Physics, Stanford University, Stanford, California 94305, USA
| | - H L H Wong
- Lawrence Berkeley National Laboratory, Berkeley, California, 94720 USA
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - S C F Wong
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - E Worcester
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - D R Wu
- Institute of High Energy Physics, Beijing
| | - F L Wu
- Nanjing University, Nanjing
| | - Q Wu
- Shandong University, Jinan
| | - W J Wu
- Institute of High Energy Physics, Beijing
| | - D M Xia
- Chongqing University, Chongqing
| | - Z Q Xie
- Institute of High Energy Physics, Beijing
| | - Z Z Xing
- Institute of High Energy Physics, Beijing
| | - J L Xu
- Institute of High Energy Physics, Beijing
| | - T Xu
- Department of Engineering Physics, Tsinghua University, Beijing
| | - T Xue
- Department of Engineering Physics, Tsinghua University, Beijing
| | - C G Yang
- Institute of High Energy Physics, Beijing
| | - L Yang
- Dongguan University of Technology, Dongguan
| | - Y Z Yang
- Department of Engineering Physics, Tsinghua University, Beijing
| | - H F Yao
- Institute of High Energy Physics, Beijing
| | - M Ye
- Institute of High Energy Physics, Beijing
| | - M Yeh
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - B L Young
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011 USA
| | - H Z Yu
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - Z Y Yu
- Institute of High Energy Physics, Beijing
| | - B B Yue
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - S Zeng
- Institute of High Energy Physics, Beijing
| | - Y Zeng
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - L Zhan
- Institute of High Energy Physics, Beijing
| | - C Zhang
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - F Y Zhang
- Department of Physics and Astronomy, Shanghai Jiao Tong University, Shanghai Laboratory for Particle Physics and Cosmology, Shanghai
| | - H H Zhang
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - J W Zhang
- Institute of High Energy Physics, Beijing
| | - Q M Zhang
- Department of Nuclear Science and Technology, School of Energy and Power Engineering, Xi'an Jiaotong University, Xi'an
| | - X T Zhang
- Institute of High Energy Physics, Beijing
| | - Y M Zhang
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - Y X Zhang
- China General Nuclear Power Group, Shenzhen
| | - Y Y Zhang
- Department of Physics and Astronomy, Shanghai Jiao Tong University, Shanghai Laboratory for Particle Physics and Cosmology, Shanghai
| | - Z J Zhang
- Dongguan University of Technology, Dongguan
| | - Z P Zhang
- University of Science and Technology of China, Hefei
| | - Z Y Zhang
- Institute of High Energy Physics, Beijing
| | - J Zhao
- Institute of High Energy Physics, Beijing
| | - L Zhou
- Institute of High Energy Physics, Beijing
| | - H L Zhuang
- Institute of High Energy Physics, Beijing
| |
Collapse
|
20
|
Sherr JL, Buckingham BA, Forlenza GP, Galderisi A, Ekhlaspour L, Wadwa RP, Carria L, Hsu L, Berget C, Peyser TA, Lee JB, O'Connor J, Dumais B, Huyett LM, Layne JE, Ly TT. Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions. Diabetes Technol Ther 2020; 22:174-184. [PMID: 31596130 PMCID: PMC7047109 DOI: 10.1089/dia.2019.0286] [Citation(s) in RCA: 53] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Background: The objective of this study was to assess the safety and performance of the Omnipod® personalized model predictive control (MPC) algorithm in adults, adolescents, and children aged ≥6 years with type 1 diabetes (T1D) under free-living conditions using an investigational device. Materials and Methods: A 96-h hybrid closed-loop (HCL) study was conducted in a supervised hotel/rental home setting following a 7-day outpatient standard therapy (ST) phase. Eligible participants were aged 6-65 years with A1C <10.0% using insulin pump therapy or multiple daily injections. Meals during HCL were unrestricted, with boluses administered per usual routine. There was daily physical activity. The primary endpoints were percentage of time with sensor glucose <70 and ≥250 mg/dL. Results: Participants were 11 adults, 10 adolescents, and 15 children aged (mean ± standard deviation) 28.8 ± 7.9, 14.3 ± 1.3, and 9.9 ± 1.0 years, respectively. Percentage time ≥250 mg/dL during HCL was 4.5% ± 4.2%, 3.5% ± 5.0%, and 8.6% ± 8.8% per respective age group, a 1.6-, 3.4-, and 2.0-fold reduction compared to ST (P = 0.1, P = 0.02, and P = 0.03). Percentage time <70 mg/dL during HCL was 1.9% ± 1.3%, 2.5% ± 2.0%, and 2.2% ± 1.9%, a statistically significant decrease in adults when compared to ST (P = 0.005, P = 0.3, and P = 0.3). Percentage time 70-180 mg/dL increased during HCL compared to ST, reaching significance for adolescents and children: HCL 73.7% ± 7.5% vs. ST 68.0% ± 15.6% for adults (P = 0.08), HCL 79.0% ± 12.6% vs. ST 60.6% ± 13.4% for adolescents (P = 0.01), and HCL 69.2% ± 13.5% vs. ST 54.9% ± 12.9% for children (P = 0.003). Conclusions: The Omnipod personalized MPC algorithm was safe and performed well over 5 days and 4 nights of use by a cohort of participants ranging from youth aged ≥6 years to adults with T1D under supervised free-living conditions with challenges, including daily physical activity and unrestricted meals.
Collapse
Affiliation(s)
- Jennifer L. Sherr
- Division of Pediatric Endocrinology & Diabetes, Department of Pediatrics, Yale University, New Haven, Connecticut
- Address correspondence to: Jennifer L. Sherr, MD, PhD, Division of Pediatric Endocrinology & Diabetes, Department of Pediatrics, Yale University, One Long Wharf Drive Suite 503, New Haven, CT 06511
| | - Bruce A. Buckingham
- Division of Pediatric Endocrinology, Department of Pediatrics, Stanford University, Stanford, California
| | - Gregory P. Forlenza
- Barbara Davis Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado
| | - Alfonso Galderisi
- Division of Pediatric Endocrinology & Diabetes, Department of Pediatrics, Yale University, New Haven, Connecticut
| | - Laya Ekhlaspour
- Division of Pediatric Endocrinology, Department of Pediatrics, Stanford University, Stanford, California
| | - R. Paul Wadwa
- Barbara Davis Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado
| | - Lori Carria
- Division of Pediatric Endocrinology & Diabetes, Department of Pediatrics, Yale University, New Haven, Connecticut
| | - Liana Hsu
- Division of Pediatric Endocrinology, Department of Pediatrics, Stanford University, Stanford, California
| | - Cari Berget
- Barbara Davis Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Affiliation(s)
- J. O'Connor
- Departments of Medicine and Nuclear Medicine Auckland Hospital Auckland. I New Zealand
| | - M. Rutland
- Departments of Medicine and Nuclear Medicine Auckland Hospital Auckland. I New Zealand
| |
Collapse
|
22
|
Affiliation(s)
- J. O'Connor
- Renal Unit Auckland Hospital Auckland. NEW ZEALAND
| | - P. Frankish
- Renal Unit Auckland Hospital Auckland. NEW ZEALAND
| |
Collapse
|
23
|
Walton MJ, O'Connor J, Carroll C, Claxton L, Hodgson R. A Review of Issues Affecting the Efficiency of Decision Making in the NICE Single Technology Appraisal Process. Pharmacoecon Open 2019; 3:403-410. [PMID: 30617953 PMCID: PMC6710310 DOI: 10.1007/s41669-018-0113-0] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
BACKGROUND Escalating demands upon the National Institute for Health and Care Excellence's (NICE's) Single Technology Appraisal (STA) programme require a 2.5-times increase upon 2015 capacity by 2020. This additional strain on committee resources threatens to compromise the rigour of the STA process. In 2018, NICE introduced changes to the appraisal process, aiming to expedite final decisions, including consultation opportunities prior to the company's evidence submission, a 'Technical Engagement' stage prior to the first committee meeting, and powers for committee chairs to recommend technologies without a second formal meeting. OBJECTIVE This study reviews recent STAs and aims to understand why appraisals require multiple meetings, and whether recent reforms can address the underlying issues. METHODS NICE STAs published between January 2010 and January 2018 were reviewed, excluding updates or re-considerations. Data on cost, clinical, and decision-making outcomes from 146 appraisals were extracted and analysed thematically. RESULTS Drugs for advanced cancers were least likely to be recommended (28/43 [65.1%] vs 71/74 [96%] for non-cancer) and took longer (2.36 meetings for a final decision vs 1.97 for non-cancer). The academic review increased upon the company's base-case incremental cost-effectiveness ratio by a median of 32.7%. Eighty-four technologies (57.5%) received a negative preliminary recommendation, deferring a final decision by an average of 142 days. Of these, 85.1% were not considered cost-effective. Uncertainty in economic (34.3%) and clinical (22.3%) data also prevented a positive decision. The majority (72.6% [61/84]) of negative preliminary decisions were overturned following further committee discussion; important considerations were Patient Access Schemes, decision optimisation, and the Cancer Drugs Fund. CONCLUSIONS Value considerations are the primary driver of negative preliminary recommendations. It is unclear if new opportunities for additional interaction between NICE, review groups, and manufacturers will meaningfully improve the efficiency of the appraisal process, particularly given the proportion of technologies requiring further committee discussion for decision optimisation or admission into the CDF.
Collapse
Affiliation(s)
- M J Walton
- Centre for Reviews and Dissemination, University of York, York, UK.
| | - J O'Connor
- Centre for Reviews and Dissemination, University of York, York, UK
| | - C Carroll
- School of Health and Related Research, University of Sheffield, Sheffield, UK
| | - L Claxton
- Centre for Reviews and Dissemination, University of York, York, UK
| | - R Hodgson
- Centre for Reviews and Dissemination, University of York, York, UK
| |
Collapse
|
24
|
Marti FEM, Jayson GC, Manoharan P, O'Connor J, Renehan AG, Backen AC, Mistry H, Ortega F, Li K, Simpson KL, Allen J, Connell J, Underhill S, Misra V, Williams KJ, Stratford I, Jackson A, Dive C, Saunders MP. Novel phase I trial design to evaluate the addition of cediranib or selumetinib to preoperative chemoradiotherapy for locally advanced rectal cancer: the DREAMtherapy trial. Eur J Cancer 2019; 117:48-59. [PMID: 31229949 DOI: 10.1016/j.ejca.2019.04.029] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2019] [Accepted: 04/21/2019] [Indexed: 10/26/2022]
Abstract
BACKGROUND The DREAMtherapy (Dual REctal Angiogenesis MEK inhibition radiotherapy) trial is a novel intertwined design whereby two tyrosine kinase inhibitors (cediranib and selumetinib) were independently evaluated with rectal chemoradiotherapy (CRT) in an efficient manner to limit the extended follow-up period often required for radiotherapy studies. PATIENTS AND METHODS Cediranib or selumetinib was commenced 10 days before and then continued with RT (45 Gy/25#/5 wks) and capecitabine (825 mg/m2 twice a day (BID)). When three patients in the cediranib 15-mg once daily (OD) cohort were in the surveillance period, recruitment to the selumetinib cohort commenced. This alternating schedule was followed throughout. Three cediranib (15, 20 and 30 mg OD) and two selumetinib cohorts (50 and 75 mg BID) were planned. Circulating and imaging biomarkers of inflammation/angiogenesis were evaluated. RESULTS In case of cediranib, dose-limiting diarrhoea, fatigue and skin reactions were seen in the 30-mg OD cohort, and therefore, 20 mg OD was defined as the maximum tolerated dose. Forty-one percent patients achieved a clinical or pathological complete response (7/17), and 53% (9/17) had an excellent clinical or pathological response (ECPR). Significantly lower level of pre-treatment plasma tumour necrosis factor alpha (TNFα) was found in patients who had an ECPR. In case of selumetinib, the 50-mg BID cohort was poorly tolerated (fatigue and diarrhoea); a reduced dose cohort of 75-mg OD was opened which was also poorly tolerated, and further recruitment was abandoned. Of the 12 patients treated, two attained an ECPR (17%). CONCLUSIONS This novel intertwined trial design is an effective way to independently investigate multiple agents with radiotherapy. The combination of cediranib with CRT was well tolerated with encouraging efficacy. TNFα emerged as a potential predictive biomarker of response and warrants further evaluation.
Collapse
Affiliation(s)
| | - G C Jayson
- The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
| | - P Manoharan
- The Christie NHS Foundation Trust, Manchester, UK; Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK
| | - J O'Connor
- The Christie NHS Foundation Trust, Manchester, UK; Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK
| | - A G Renehan
- The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
| | - A C Backen
- The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
| | - H Mistry
- Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, M13 9PT, UK
| | - F Ortega
- Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, M13 9PT, UK
| | - K Li
- Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK
| | - K L Simpson
- Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, UK
| | - J Allen
- The Christie NHS Foundation Trust, Manchester, UK
| | - J Connell
- The Christie NHS Foundation Trust, Manchester, UK
| | - S Underhill
- The Christie NHS Foundation Trust, Manchester, UK
| | - V Misra
- The Christie NHS Foundation Trust, Manchester, UK
| | - K J Williams
- Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, M13 9PT, UK; Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK
| | - I Stratford
- Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, M13 9PT, UK
| | - A Jackson
- Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK
| | - C Dive
- Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, UK
| | - M P Saunders
- The Christie NHS Foundation Trust, Manchester, UK.
| |
Collapse
|
25
|
Forlenza GP, Buckingham BA, Christiansen MP, Wadwa RP, Peyser TA, Lee JB, O'Connor J, Dassau E, Huyett LM, Layne JE, Ly TT. Performance of Omnipod Personalized Model Predictive Control Algorithm with Moderate Intensity Exercise in Adults with Type 1 Diabetes. Diabetes Technol Ther 2019; 21:265-272. [PMID: 30925077 PMCID: PMC6532546 DOI: 10.1089/dia.2019.0017] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Background: The objective of this study was to assess the safety and performance of the Omnipod® personalized model predictive control (MPC) algorithm with variable glucose setpoints and moderate intensity exercise using an investigational device in adults with type 1 diabetes (T1D). Materials and Methods: A supervised 54-h hybrid closed-loop (HCL) study was conducted in a hotel setting after a 7-day outpatient standard treatment phase. Adults aged 18-65 years with T1D and HbA1c between 6.0% and 10.0% were eligible. Subjects completed two moderate intensity exercise sessions of >30 min duration on consecutive days: the first with the glucose set point increased from 130 to 150 mg/dL and the second with a temporary basal rate of 50%, both started 90 min pre-exercise. Primary endpoints were percentage time in hypoglycemia <70 mg/dL and hyperglycemia ≥250 mg/dL. Results: Twelve subjects participated in the study, with (mean ± standard deviation) age 36.5 ± 14.4 years, diabetes duration 21.7 ± 15.7 years, HbA1c 7.6% ± 1.1%, and total daily dose 0.60 ± 0.22 U/kg. Outcomes for the 54-h HCL period were mean glucose: 136 ± 14 mg/dL, percentage time <70 mg/dL: 1.4% ± 1.3%, 70-180 mg/dL: 85.1% ± 9.3%, and ≥250 mg/dL: 1.8% ± 2.4%. In the 12-h period after exercise start, percentage time <70 mg/dL was 1.4% ± 2.7% with the raised glucose set point and 1.6% ± 3.0% with reduced basal rate. The percentage time <70 mg/dL overnight was 0% ± 0% on both study nights. Conclusions: The Omnipod personalized MPC algorithm performed well and was safe during day and night use in response to variable glucose set points and with temporarily raised glucose set point or reduced basal rate 90 min in advance of moderate intensity exercise in adults with T1D.
Collapse
Affiliation(s)
- Gregory P. Forlenza
- Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, Colorado
- Address correspondence to: Gregory P. Forlenza, MD, Barbara Davis Center for Diabetes, University of Colorado School of Medicine, 1775 Aurora CT, MS A140, Aurora, CO 80045
| | - Bruce A. Buckingham
- Division of Pediatric Endocrinology, Department of Pediatrics, Stanford University, Stanford, California
| | | | - R. Paul Wadwa
- Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, Colorado
| | | | | | | | - Eyal Dassau
- Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts
| | | | | | | |
Collapse
|
26
|
Williams J, Tu S, Lodhia C, Gu G, Haar G, O'Connor J, Niewiadomski O, Tandiari T, Nicoll A. Parenteral nutrition: How do patients initiated in the intensive care unit differ from those on the ward? Clinical Nutrition Experimental 2019. [DOI: 10.1016/j.yclnex.2019.01.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
27
|
Adamson P, Anghel I, Aurisano A, Barr G, Bishai M, Blake A, Bock GJ, Bogert D, Cao SV, Carroll TJ, Castromonte CM, Chen R, Childress S, Coelho JAB, Corwin L, Cronin-Hennessy D, de Jong JK, De Rijck S, Devan AV, Devenish NE, Diwan MV, Escobar CO, Evans JJ, Falk E, Feldman GJ, Flanagan W, Frohne MV, Gabrielyan M, Gallagher HR, Germani S, Gomes RA, Goodman MC, Gouffon P, Graf N, Gran R, Grzelak K, Habig A, Hahn SR, Hartnell J, Hatcher R, Holin A, Huang J, Hylen J, Irwin GM, Isvan Z, James C, Jensen D, Kafka T, Kasahara SMS, Koerner LW, Koizumi G, Kordosky M, Kreymer A, Lang K, Ling J, Litchfield PJ, Lucas P, Mann WA, Marshak ML, Mayer N, McGivern C, Medeiros MM, Mehdiyev R, Meier JR, Messier MD, Miller WH, Mishra SR, Moed Sher S, Moore CD, Mualem L, Musser J, Naples D, Nelson JK, Newman HB, Nichol RJ, Nowak JA, O'Connor J, Orchanian M, Pahlka RB, Paley J, Patterson RB, Pawloski G, Perch A, Pfützner MM, Phan DD, Phan-Budd S, Plunkett RK, Poonthottathil N, Qiu X, Radovic A, Rebel B, Rosenfeld C, Rubin HA, Sail P, Sanchez MC, Schneps J, Schreckenberger A, Schreiner P, Sharma R, Sousa A, Tagg N, Talaga RL, Thomas J, Thomson MA, Tian X, Timmons A, Todd J, Tognini SC, Toner R, Torretta D, Tzanakos G, Urheim J, Vahle P, Viren B, Weber A, Webb RC, White C, Whitehead LH, Wojcicki SG, Zwaska R. Search for Sterile Neutrinos in MINOS and MINOS+ Using a Two-Detector Fit. Phys Rev Lett 2019; 122:091803. [PMID: 30932529 DOI: 10.1103/physrevlett.122.091803] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/23/2017] [Revised: 05/30/2018] [Indexed: 06/09/2023]
Abstract
A search for mixing between active neutrinos and light sterile neutrinos has been performed by looking for muon neutrino disappearance in two detectors at baselines of 1.04 and 735 km, using a combined MINOS and MINOS+ exposure of 16.36×10^{20} protons on target. A simultaneous fit to the charged-current muon neutrino and neutral-current neutrino energy spectra in the two detectors yields no evidence for sterile neutrino mixing using a 3+1 model. The most stringent limit to date is set on the mixing parameter sin^{2}θ_{24} for most values of the sterile neutrino mass splitting Δm_{41}^{2}>10^{-4} eV^{2}.
Collapse
Affiliation(s)
- P Adamson
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - I Anghel
- Argonne National Laboratory, Argonne, Illinois 60439, USA
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011 USA
| | - A Aurisano
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - G Barr
- Subdepartment of Particle Physics, University of Oxford, Oxford OX1 3RH, United Kingdom
| | - M Bishai
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - A Blake
- Cavendish Laboratory, University of Cambridge, Cambridge CB3 0HE, United Kingdom
- Lancaster University, Lancaster LA1 4YB, United Kingdom
| | - G J Bock
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - D Bogert
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - S V Cao
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - T J Carroll
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - C M Castromonte
- Instituto de Física, Universidade Federal de Goiás, 74690-900 Goiânia, GO, Brazil
| | - R Chen
- School of Physics and Astronomy, University of Manchester, Manchester M13 9PL, United Kingdom
| | - S Childress
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - J A B Coelho
- Physics Department, Tufts University, Medford, Massachusetts 02155, USA
| | - L Corwin
- Indiana University, Bloomington, Indiana 47405, USA
| | | | - J K de Jong
- Subdepartment of Particle Physics, University of Oxford, Oxford OX1 3RH, United Kingdom
| | - S De Rijck
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - A V Devan
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
| | - N E Devenish
- Department of Physics and Astronomy, University of Sussex, Falmer, Brighton BN1 9QH, United Kingdom
| | - M V Diwan
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - C O Escobar
- Universidade Estadual de Campinas, IFGW, CP 6165, 13083-970 Campinas, SP, Brazil
| | - J J Evans
- School of Physics and Astronomy, University of Manchester, Manchester M13 9PL, United Kingdom
| | - E Falk
- Department of Physics and Astronomy, University of Sussex, Falmer, Brighton BN1 9QH, United Kingdom
| | - G J Feldman
- Department of Physics, Harvard University, Cambridge, Massachusetts 02138, USA
| | - W Flanagan
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - M V Frohne
- Holy Cross College, Notre Dame, Indiana 46556, USA
| | - M Gabrielyan
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - H R Gallagher
- Physics Department, Tufts University, Medford, Massachusetts 02155, USA
| | - S Germani
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - R A Gomes
- Instituto de Física, Universidade Federal de Goiás, 74690-900 Goiânia, GO, Brazil
| | - M C Goodman
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - P Gouffon
- Instituto de Física, Universidade de São Paulo, CP 66318, 05315-970 São Paulo, SP, Brazil
| | - N Graf
- Department of Physics and Astronomy, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA
| | - R Gran
- Department of Physics, University of Minnesota Duluth, Duluth, Minnesota 55812, USA
| | - K Grzelak
- Department of Physics, University of Warsaw, PL-02-093 Warsaw, Poland
| | - A Habig
- Department of Physics, University of Minnesota Duluth, Duluth, Minnesota 55812, USA
| | - S R Hahn
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - J Hartnell
- Department of Physics and Astronomy, University of Sussex, Falmer, Brighton BN1 9QH, United Kingdom
| | - R Hatcher
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - A Holin
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - J Huang
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - J Hylen
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - G M Irwin
- Department of Physics, Stanford University, Stanford, California 94305, USA
| | - Z Isvan
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - C James
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - D Jensen
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - T Kafka
- Physics Department, Tufts University, Medford, Massachusetts 02155, USA
| | - S M S Kasahara
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - L W Koerner
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - G Koizumi
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - M Kordosky
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
| | - A Kreymer
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - K Lang
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - J Ling
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - P J Litchfield
- University of Minnesota, Minneapolis, Minnesota 55455, USA
- Rutherford Appleton Laboratory, Science and Technology Facilities Council, Didcot OX11 0QX, United Kingdom
| | - P Lucas
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - W A Mann
- Physics Department, Tufts University, Medford, Massachusetts 02155, USA
| | - M L Marshak
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - N Mayer
- Physics Department, Tufts University, Medford, Massachusetts 02155, USA
| | - C McGivern
- Department of Physics and Astronomy, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA
| | - M M Medeiros
- Instituto de Física, Universidade Federal de Goiás, 74690-900 Goiânia, GO, Brazil
| | - R Mehdiyev
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - J R Meier
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - M D Messier
- Indiana University, Bloomington, Indiana 47405, USA
| | - W H Miller
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - S R Mishra
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - S Moed Sher
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - C D Moore
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - L Mualem
- Lauritsen Laboratory, California Institute of Technology, Pasadena, California 91125, USA
| | - J Musser
- Indiana University, Bloomington, Indiana 47405, USA
| | - D Naples
- Department of Physics and Astronomy, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA
| | - J K Nelson
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
| | - H B Newman
- Lauritsen Laboratory, California Institute of Technology, Pasadena, California 91125, USA
| | - R J Nichol
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - J A Nowak
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - J O'Connor
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - M Orchanian
- Lauritsen Laboratory, California Institute of Technology, Pasadena, California 91125, USA
| | - R B Pahlka
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - J Paley
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - R B Patterson
- Lauritsen Laboratory, California Institute of Technology, Pasadena, California 91125, USA
| | - G Pawloski
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - A Perch
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - M M Pfützner
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - D D Phan
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - S Phan-Budd
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - R K Plunkett
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - N Poonthottathil
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - X Qiu
- Department of Physics, Stanford University, Stanford, California 94305, USA
| | - A Radovic
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
| | - B Rebel
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - C Rosenfeld
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - H A Rubin
- Department of Physics, Illinois Institute of Technology, Chicago, Illinois 60616, USA
| | - P Sail
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - M C Sanchez
- Argonne National Laboratory, Argonne, Illinois 60439, USA
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011 USA
| | - J Schneps
- Physics Department, Tufts University, Medford, Massachusetts 02155, USA
| | - A Schreckenberger
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - P Schreiner
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - R Sharma
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - A Sousa
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - N Tagg
- Otterbein University, Westerville, Ohio 43081, USA
| | - R L Talaga
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - J Thomas
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - M A Thomson
- Cavendish Laboratory, University of Cambridge, Cambridge CB3 0HE, United Kingdom
| | - X Tian
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - A Timmons
- School of Physics and Astronomy, University of Manchester, Manchester M13 9PL, United Kingdom
| | - J Todd
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - S C Tognini
- Instituto de Física, Universidade Federal de Goiás, 74690-900 Goiânia, GO, Brazil
| | - R Toner
- Department of Physics, Harvard University, Cambridge, Massachusetts 02138, USA
| | - D Torretta
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - G Tzanakos
- Department of Physics, University of Athens, GR-15771 Athens, Greece
| | - J Urheim
- Indiana University, Bloomington, Indiana 47405, USA
| | - P Vahle
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
| | - B Viren
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - A Weber
- Subdepartment of Particle Physics, University of Oxford, Oxford OX1 3RH, United Kingdom
- Rutherford Appleton Laboratory, Science and Technology Facilities Council, Didcot OX11 0QX, United Kingdom
| | - R C Webb
- Physics Department, Texas A&M University, College Station, Texas 77843, USA
| | - C White
- Department of Physics, Illinois Institute of Technology, Chicago, Illinois 60616, USA
| | - L H Whitehead
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - S G Wojcicki
- Department of Physics, Stanford University, Stanford, California 94305, USA
| | - R Zwaska
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| |
Collapse
|
28
|
Yoshino T, Portnoy DC, Obermannová R, Bodoky G, Prausová J, Garcia-Carbonero R, Ciuleanu T, García-Alfonso P, Cohn AL, Van Cutsem E, Yamazaki K, Lonardi S, Muro K, Kim TW, Yamaguchi K, Grothey A, O'Connor J, Taieb J, Wijayawardana SR, Hozak RR, Nasroulah F, Tabernero J. Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study. Ann Oncol 2019; 30:124-131. [PMID: 30339194 PMCID: PMC6336001 DOI: 10.1093/annonc/mdy461] [Citation(s) in RCA: 39] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Background : Second-line treatment with ramucirumab+FOLFIRI improved overall survival (OS) versus placebo+FOLFIRI for patients with metastatic colorectal carcinoma (CRC) [hazard ratio (HR)=0.84, 95% CI 0.73-0.98, P = 0.022]. Post hoc analyses of RAISE patient data examined the association of RAS/RAF mutation status and the anatomical location of the primary CRC tumour (left versus right) with efficacy parameters. Patients and methods Patient tumour tissue was classified as BRAF mutant, KRAS/NRAS (RAS) mutant, or RAS/BRAF wild-type. Left-CRC was defined as the splenic flexure, descending and sigmoid colon, and rectum; right-CRC included transverse, ascending colon, and cecum. Results RAS/RAF mutation status was available for 85% of patients (912/1072) and primary tumour location was known for 94.4% of patients (1012/1072). A favourable and comparable ramucirumab treatment effect was observed for patients with RAS mutations (OS HR = 0.86, 95% CI 0.71-1.04) and patients with RAS/BRAF wild-type tumours (OS HR = 0.86, 95% CI 0.64-1.14). Among the 41 patients with BRAF-mutated tumours, the ramucirumab benefit was more notable (OS HR = 0.54, 95% CI 0.25-1.13), although, as with the other genetic sub-group analyses, differences were not statistically significant. Progression-free survival (PFS) data followed the same trend. Treatment-by-mutation status interaction tests (OS P = 0.523, PFS P = 0.655) indicated that the ramucirumab benefit was not statistically different among the mutation sub-groups, although the small sample size of the BRAF group limited the analysis. Addition of ramucirumab to FOLFIRI improved left-CRC median OS by 2.5 month over placebo (HR = 0.81, 95% CI 0.68-0.97); median OS for ramucirumab-treated patients with right-CRC was 1.1 month over placebo (HR = 0.97, 95% CI 0.75-1.26). The treatment-by-sub-group interaction was not statistically significant for tumour sidedness (P = 0.276). Conclusions In the RAISE study, the addition of ramucirumab to FOLFIRI improved patient outcomes, regardless of RAS/RAF mutation status, and tumour sidedness. Ramucirumab treatment provided a numerically substantial benefit in BRAF-mutated tumours, although the P-values were not statistically significant. ClinicalTrials.gov number NCT01183780.
Collapse
Affiliation(s)
- T Yoshino
- National Cancer Center Hospital East, Kashiwa, Japan.
| | | | | | - G Bodoky
- St. Laszlo Hospital, Budapest, Hungary
| | - J Prausová
- Fakultni Nemocnice v MOTOLE, Prague, Czech Republic
| | - R Garcia-Carbonero
- Hospital Universitario Doce de Octubre, IIS imas12, UCM, CNIO, CIBERONC, Madrid, Spain
| | - T Ciuleanu
- Institutul Oncologic Ion Chiricuta and UMF Iuliu Hatieganu, Cluj-Napoca, Romania
| | | | - A L Cohn
- Rocky Mountain Cancer Center, LLP, Denver, USA
| | - E Van Cutsem
- Univ Hospital Gasthuisberg Leuven and KU Leuven, Leuven, Belgium
| | | | - S Lonardi
- Istituto Oncologico Veneto-IRCCS, Padova, Italy
| | - K Muro
- Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
| | - T W Kim
- Asan Medical Center, University of Ulsan, Seoul, Republic of Korea
| | - K Yamaguchi
- The Cancer Institute Hospital of JFCR, Tokyo, Japan
| | | | - J O'Connor
- Instituto Alexander Fleming, Buenos Aires, Argentina
| | - J Taieb
- Sorbonne Paris Cité, Paris Descartes University, Georges Pompidou European Hospital, Paris, France
| | | | - R R Hozak
- Eli Lilly and Company, Indianapolis, USA
| | - F Nasroulah
- Eli Lilly and Company, Buenos Aires, Argentina
| | - J Tabernero
- Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain
| |
Collapse
|
29
|
Murrin C, O'Connor J, Doyle G, Delany L, Lades L, O'Malley G, Lawlor O, Harold L, Mullins B, Fitzpatrick P. Removing sugar sweetened beverages from a university campus. Eur J Public Health 2018. [DOI: 10.1093/eurpub/cky214.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- C Murrin
- School of Public Health, University College Dublin, Dublin, Ireland
| | - J O'Connor
- Quinn School of Business, University College Dublin, Dublin, Ireland
| | - G Doyle
- Quinn School of Business, University College Dublin, Dublin, Ireland
| | - L Delany
- Geary Institute for Public Policy, University College Dublin, Dublin, Ireland
| | - L Lades
- Geary Institute for Public Policy, University College Dublin, Dublin, Ireland
| | - G O'Malley
- Division of Population Health Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - O Lawlor
- Hospitality Services, University College Dublin, Dublin, Ireland
| | | | | | - P Fitzpatrick
- School of Public Health, University College Dublin, Dublin, Ireland
| |
Collapse
|
30
|
Buckingham BA, Christiansen MP, Forlenza GP, Wadwa RP, Peyser TA, Lee JB, O'Connor J, Dassau E, Huyett LM, Layne JE, Ly TT. Performance of the Omnipod Personalized Model Predictive Control Algorithm with Meal Bolus Challenges in Adults with Type 1 Diabetes. Diabetes Technol Ther 2018; 20:585-595. [PMID: 30070928 PMCID: PMC6114075 DOI: 10.1089/dia.2018.0138] [Citation(s) in RCA: 34] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
BACKGROUND This study assessed the safety and performance of the Omnipod® personalized model predictive control (MPC) algorithm using an investigational device in adults with type 1 diabetes in response to overestimated and missed meal boluses and extended boluses for high-fat meals. MATERIALS AND METHODS A supervised 54-h hybrid closed-loop (HCL) study was conducted in a hotel setting after a 7-day outpatient open-loop run-in phase. Adults aged 18-65 years with type 1 diabetes and HbA1c 6.0%-10.0% were eligible. Primary endpoints were percentage time in hypoglycemia <70 mg/dL and hyperglycemia ≥250 mg/dL. Glycemic responses for 4 h to a 130% overestimated bolus and a missed meal bolus were compared with a 100% bolus for identical meals, respectively. The 12-h postprandial responses to a high-fat meal were compared using either a standard or extended bolus. RESULTS Twelve subjects participated in the study, with (mean ± standard deviation): age 35.4 ± 14.1 years, diabetes duration 16.5 ± 9.3 years, HbA1c 7.7 ± 0.9%, and total daily dose 0.58 ± 0.19 U/kg. Outcomes for the 54-h HCL period were mean glucose 153 ± 15 mg/dL, percentage time <70 mg/dL [median (interquartile range)]: 0.0% (0.0-1.2%), 70-180 mg/dL: 76.1% ± 8.0%, and ≥250 mg/dL: 4.5% ± 3.6%. After both the 100% and 130% boluses, postprandial percentage time <70 mg/dL was 0.0% (0.0-0.0%) (P = 0.50). After the 100% and missed boluses, postprandial percentage time ≥250 mg/dL was 0.2% ± 0.6% and 10.3% ± 16.5%, respectively (P = 0.06). Postprandial percentages time ≥250 mg/dL and <70 mg/dL were similar with standard or extended boluses for a high-fat meal. CONCLUSIONS The Omnipod personalized MPC algorithm performed well and was safe during day and night use in response to overestimated, missed, and extended meal boluses in adults with type 1 diabetes.
Collapse
Affiliation(s)
- Bruce A. Buckingham
- Division of Pediatric Endocrinology, Department of Pediatrics, Stanford University, Stanford, California
- Address correspondence to:Bruce A. Buckingham, MDDivision of Endocrinology and DiabetesStanford School of Medicine780 Welch RoadPalo Alto, CA 94305
| | | | - Gregory P. Forlenza
- Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, Colorado
| | - R. Paul Wadwa
- Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, Colorado
| | | | | | | | - Eyal Dassau
- Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts
| | | | | | - Trang T. Ly
- Insulet Corporation, Billerica, Massachusetts
| |
Collapse
|
31
|
Salem A, Gorman D, Mistry H, Joseph L, Shah R, Valentine H, Jackson A, West C, Faivre-Finn C, O'Connor J, Asselin M. OC-0267: Technical and biological validation of hypoxia PET imaging using [18F]fluroazomycin (FAZA) in NSCLC. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)30577-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
32
|
Buckingham BA, Forlenza GP, Pinsker JE, Christiansen MP, Wadwa RP, Schneider J, Peyser TA, Dassau E, Lee JB, O'Connor J, Layne JE, Ly TT. Safety and Feasibility of the OmniPod Hybrid Closed-Loop System in Adult, Adolescent, and Pediatric Patients with Type 1 Diabetes Using a Personalized Model Predictive Control Algorithm. Diabetes Technol Ther 2018; 20:257-262. [PMID: 29431513 PMCID: PMC5910038 DOI: 10.1089/dia.2017.0346] [Citation(s) in RCA: 52] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
BACKGROUND The safety and feasibility of the OmniPod personalized model predictive control (MPC) algorithm in adult, adolescent, and pediatric patients with type 1 diabetes were investigated. METHODS This multicenter, observational trial included a 1-week outpatient sensor-augmented pump open-loop phase and a 36-h inpatient hybrid closed-loop (HCL) phase with announced meals ranging from 30 to 90 g of carbohydrates and limited physical activity. Patients aged 6-65 years with HbA1c between 6.0% and 10.0% were eligible. The investigational system included a modified version of OmniPod, the Dexcom G4 505 Share® AP System, and the personalized MPC algorithm running on a tablet computer. Primary endpoints included sensor glucose percentage of time in hypoglycemia <70 mg/dL and hyperglycemia >250 mg/dL. Additional glycemic targets were assessed. RESULTS The percentage of time <70 mg/dL during the 36-h HCL phase was mean (standard deviation): 0.7 (1.7) in adults receiving 80% meal bolus (n = 24), and 0.7 (1.2) in adults (n = 10), 2.0 (2.4) in adolescents (n = 12), and 2.0 (2.6) in pediatrics (n = 12) receiving 100% meal bolus. The overall hypoglycemia rate was 0.49 events/24 h. The percentage of time >250 mg/dL was 8.0 (7.5), 3.6 (3.7), 4.9 (6.3), and 6.7 (5.6) in the study groups, respectively. Percentage of time in the target range of 70-180 mg/dL was 69.5 (14.4), 73.0 (15.0), 72.6 (15.5), and 70.1 (12.3), respectively. CONCLUSIONS The OmniPod personalized MPC algorithm performed well and was safe during day and night use in adult, adolescent, and pediatric patients with type 1 diabetes. Longer term studies will assess the safety and performance of the algorithm under free living conditions with extended use.
Collapse
Affiliation(s)
- Bruce A. Buckingham
- Division of Endocrinology, Department of Pediatrics, Stanford School of Medicine, Stanford, Palo Alto, California
| | - Gregory P. Forlenza
- Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, Colorado
| | | | | | - R. Paul Wadwa
- Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, Colorado
| | | | | | - Eyal Dassau
- Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts
| | | | | | | | - Trang T. Ly
- Insulet Corporation, Billerica, Massachusetts
| |
Collapse
|
33
|
Debnath S, O'Connor J, Hura C, Kasinath B, Lorenzo C. Quality of Life and Depression Among Mexican Americans on Hemodialysis: A Preliminary Report. Ther Apher Dial 2017; 22:166-170. [PMID: 29193825 DOI: 10.1111/1744-9987.12642] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2017] [Revised: 09/07/2017] [Accepted: 09/21/2017] [Indexed: 11/29/2022]
Abstract
Health-related quality of life (QOL) and depression burden of Mexican Americans with end-stage renal disease (ESRD) are not known. This observational cross-sectional study assessed QOL and depression and examined their inter-relatedness in Mexican Americans with type 2 diabetes and ESRD on maintenance hemodialysis (HD) treatment. Prevalent Mexican Americans on HD (N = 40) completed the Kidney Disease Quality of Life-Short Form (KDQOL-SF) and the Beck Depression Inventory II. The overall median scores for the mental component summary and the physical component summary scales in the KDQOL-SF were 40.9 and 34.0, respectively. The prevalence of severe depression was 40%. The most significant differences between depressed and non-depressed groups were symptom/problem list, cognitive function, and emotional well- being (P < 0.0001 for all). Mexican Americans with depression endure a more dismal QOL compared to non-depressed peers. Significant negative correlations between depression and several QOL scales underscore plausible interactions between the two conditions which warrants further evaluation.
Collapse
Affiliation(s)
- Subrata Debnath
- Department of Medicine, Division of Nephrology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
| | - Jason O'Connor
- Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.,South Texas Veterans Health Care System, San Antonio, Texas, USA
| | - Claudia Hura
- Department of Medicine, Division of Nephrology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
| | - Balakuntalam Kasinath
- Department of Medicine, Division of Nephrology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.,South Texas Veterans Health Care System, San Antonio, Texas, USA
| | - Carlos Lorenzo
- Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
| |
Collapse
|
34
|
Alcaide F, Amlerová J, Bou G, Ceyssens PJ, Coll P, Corcoran D, Fangous MS, González-Álvarez I, Gorton R, Greub G, Hery-Arnaud G, Hrábak J, Ingebretsen A, Lucey B, Marekoviċ I, Mediavilla-Gradolph C, Monté MR, O'Connor J, O'Mahony J, Opota O, O'Reilly B, Orth-Höller D, Oviaño M, Palacios JJ, Palop B, Pranada AB, Quiroga L, Rodríguez-Temporal D, Ruiz-Serrano MJ, Tudó G, Van den Bossche A, van Ingen J, Rodriguez-Sanchez B. How to: identify non-tuberculous Mycobacterium species using MALDI-TOF mass spectrometry. Clin Microbiol Infect 2017; 24:599-603. [PMID: 29174730 DOI: 10.1016/j.cmi.2017.11.012] [Citation(s) in RCA: 69] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2017] [Revised: 11/12/2017] [Accepted: 11/14/2017] [Indexed: 11/29/2022]
Abstract
BACKGROUND The implementation of MALDI-TOF MS for microorganism identification has changed the routine of the microbiology laboratories as we knew it. Most microorganisms can now be reliably identified within minutes using this inexpensive, user-friendly methodology. However, its application in the identification of mycobacteria isolates has been hampered by the structure of their cell wall. Improvements in the sample processing method and in the available database have proved key factors for the rapid and reliable identification of non-tuberculous mycobacteria isolates using MALDI-TOF MS. AIMS The main objective is to provide information about the proceedings for the identification of non-tuberculous isolates using MALDI-TOF MS and to review different sample processing methods, available databases, and the interpretation of the results. SOURCES Results from relevant studies on the use of the available MALDI-TOF MS instruments, the implementation of innovative sample processing methods, or the implementation of improved databases are discussed. CONTENT Insight about the methodology required for reliable identification of non-tuberculous mycobacteria and its implementation in the microbiology laboratory routine is provided. IMPLICATIONS Microbiology laboratories where MALDI-TOF MS is available can benefit from its capacity to identify most clinically interesting non-tuberculous mycobacteria in a rapid, reliable, and inexpensive manner.
Collapse
Affiliation(s)
- F Alcaide
- Servei de Microbiología, Hospital Universitari de Bellvitge- IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
| | - J Amlerová
- Biomedical Center, Faculty of Medicine in Plzen, Plzen, Czech Republic
| | - G Bou
- Servicio de Microbiología, Hospital Universitario A Coruña, A Coruña, Spain
| | - P J Ceyssens
- Division of Bacterial Diseases, Scientific Institute of Public Health, Brussels, Belgium
| | - P Coll
- Hospital Sant Pau i Santa Creu, Servei de Microbiologia, Barcelona, Spain
| | - D Corcoran
- Laboratory of Medicine, Diagnostic Directorate, Cork University Hospital, Bishopstown, Cork, Ireland
| | - M-S Fangous
- Laboratoire de Bactériologie, Plateforme de Biologie, Hôpital Cavale Blanche, Brest, France
| | - I González-Álvarez
- Unidad Referencia Regional de Micobacterias, Servicio de Microbiología, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - R Gorton
- Health Services Laboratories, London, UK
| | - G Greub
- Institut de Microbiologie de l'Université de Lausanne, Lausanne, Switzerland; European Study Group on Genomics and Molecular Diagnosis (ESGMD), Switzerland
| | - G Hery-Arnaud
- Laboratoire de Bactériologie, Plateforme de Biologie, Hôpital Cavale Blanche, Brest, France
| | - J Hrábak
- Biomedical Center, Faculty of Medicine in Plzen, Plzen, Czech Republic
| | - A Ingebretsen
- Dept. of Microbiology, Oslo University Hospital, Oslo, Norway
| | - B Lucey
- Department of Biological Sciences, Cork Institute of Technology, Ireland
| | - I Marekoviċ
- University of Zagreb School of Medicine, University Hospital Centre Zagreb, Department of Clinical and Molecular Microbiology, Zagreb, Croatia
| | | | - M R Monté
- Laboratori de Microbiologia-CDB, Hospital Clínic de Barcelona-ISGlobal, Departament de Fonaments Clínics, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Spain
| | - J O'Connor
- Department of Biological Sciences, Cork Institute of Technology, Ireland
| | - J O'Mahony
- Department of Biological Sciences, Cork Institute of Technology, Ireland
| | - O Opota
- Institut de Microbiologie de l'Université de Lausanne, Lausanne, Switzerland
| | - B O'Reilly
- Laboratory of Medicine, Diagnostic Directorate, Cork University Hospital, Bishopstown, Cork, Ireland
| | - D Orth-Höller
- Division of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria
| | - M Oviaño
- Servicio de Microbiología, Hospital Universitario A Coruña, A Coruña, Spain
| | - J J Palacios
- Unidad Referencia Regional de Micobacterias, Servicio de Microbiología, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - B Palop
- Laboratorio de Microbiología, Hospital Regional de Málaga, Málaga, Spain
| | - A B Pranada
- MVZ Dr. Eberhard & Partner Dortmund (ÜBAG), Department of Medical Microbiology, Dortmund, Germany
| | - L Quiroga
- Clinical Microbiology and Infectious Diseases Department, Instituto de Investigación Sanitaria Gregorio Marañón Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - D Rodríguez-Temporal
- Servei de Microbiología, Hospital Universitari de Bellvitge- IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
| | - M J Ruiz-Serrano
- European Study Group on Genomics and Molecular Diagnosis (ESGMD), Switzerland; Clinical Microbiology and Infectious Diseases Department, Instituto de Investigación Sanitaria Gregorio Marañón Hospital General Universitario Gregorio Marañón, Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES CB06/06/0058), Madrid, Spain
| | - G Tudó
- Laboratori de Microbiologia-CDB, Hospital Clínic de Barcelona-ISGlobal, Departament de Fonaments Clínics, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Spain
| | - A Van den Bossche
- Division of Bacterial Diseases, Scientific Institute of Public Health, Brussels, Belgium
| | - J van Ingen
- Department of Medical Microbiology, Radboud University Medical Centre, Nijmegen, The Netherlands
| | - B Rodriguez-Sanchez
- European Study Group on Genomics and Molecular Diagnosis (ESGMD), Switzerland; Clinical Microbiology and Infectious Diseases Department, Instituto de Investigación Sanitaria Gregorio Marañón Hospital General Universitario Gregorio Marañón, Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES CB06/06/0058), Madrid, Spain.
| | | |
Collapse
|
35
|
Affiliation(s)
- Samuel Tisherman
- Department of Surgery, University of Maryland School of Medicine, Baltimore, Maryland, USA
| | - J O'Connor
- Department of Surgery, University of Maryland School of Medicine, Baltimore, Maryland, USA
| |
Collapse
|
36
|
Morton B, Nweze K, O'Connor J, Turton P, Joekes E, Blakey JD, Welters ID. Oxygen exchange and C-reactive protein predict safe discharge in patients with H1N1 influenza. QJM 2017; 110:227-232. [PMID: 27803369 DOI: 10.1093/qjmed/hcw176] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/16/2016] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND : Pandemic influenza has potential to overwhelm healthcare resources. There is uncertainty over performance of existing triage tools for hospital admission and discharge decisions. AIM : Our aim was to identify clinical criteria that predict safe discharge from hospital and develop a pragmatic triage tool to guide physician decision-making. DESIGN : We retrospectively examined an existing database of patients who presented to the Royal Liverpool University Hospital during the 2010-11 influenza pandemic. METHODS Inclusion criteria: patients ≥18 years, with PCR confirmed H1N1 influenza. Exclusion criteria: died in the emergency department or case notes unavailable. Successful discharge was defined as discharge within 24 h of presentation and no readmission within 7 days. RESULTS Eighty-six patients were included and 16 were successfully discharged. Estimated P/F ratio and C-reactive protein predicted safe discharge in a multivariable logistic regression model (AUC 0.883). A composite univariate predictor (estimated P/F minus C-reactive protein, AUC 0.877) was created to calculate specific cut off points for sensitivity and specificity. A pragmatic decision tool was created to incorporate these thresholds and relevant guidelines. Discharge: SpO 2 (in air) ≥ 94% and CRP <50. Observe: SpO 2 ≥ 94% and CRP >50 or SpO 2 ≤ 93% and CRP <50. Admit: SpO 2 ≤ 93% and CRP >50. CONCLUSIONS We identified that oxygen exchange and CRP, a marker of acute inflammation, were the most important predictors of safe discharge. Our proposed simple triage model requires validation but has the potential to aid clinical decisions in the event of a future pandemic, and potentially for seasonal influenza.
Collapse
Affiliation(s)
- B Morton
- From the Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK
- Critical Care Department, Aintree University Hospital NHS Foundation Trust, Aintree, UK
| | - K Nweze
- Department of Critical Care Medicine, Royal Liverpool University Hospital, Liverpool, UK
| | - J O'Connor
- Department of Critical Care Medicine, Royal Liverpool University Hospital, Liverpool, UK
| | - P Turton
- Department of Critical Care Medicine, Royal Liverpool University Hospital, Liverpool, UK
| | - E Joekes
- Department of Radiology, Royal Liverpool University Hospital, Liverpool, UK
| | - J D Blakey
- From the Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK
- Critical Care Department, Aintree University Hospital NHS Foundation Trust, Aintree, UK
| | - I D Welters
- Department of Critical Care Medicine, Royal Liverpool University Hospital, Liverpool, UK
- Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK
| |
Collapse
|
37
|
McCann EP, Williams KL, Fifita JA, Tarr IS, O'Connor J, Rowe DB, Nicholson GA, Blair IP. The genotype-phenotype landscape of familial amyotrophic lateral sclerosis in Australia. Clin Genet 2017; 92:259-266. [PMID: 28105640 DOI: 10.1111/cge.12973] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2016] [Revised: 01/12/2017] [Accepted: 01/14/2017] [Indexed: 12/19/2022]
Abstract
Amyotrophic lateral sclerosis (ALS) is a clinically and genetically heterogeneous fatal neurodegenerative disease. Around 10% of ALS cases are hereditary. ALS gene discoveries have provided most of our understanding of disease pathogenesis. We aimed to describe the genetic landscape of ALS in Australia by assessing 1013 Australian ALS patients for known ALS mutations by direct sequencing, whole exome sequencing or repeat primed polymerase chain reaction. Age of disease onset and disease duration were used for genotype-phenotype correlations. We report 60.8% of Australian ALS families in this cohort harbour a known ALS mutation. Hexanucleotide repeat expansions in C9orf72 accounted for 40.6% of families and 2.9% of sporadic patients. We also report ALS families with mutations in SOD1 (13.7%), FUS (2.4%), TARDBP (1.9%), UBQLN2 (.9%), OPTN (.5%), TBK1 (.5%) and CCNF (.5%). We present genotype-phenotype correlations between these genes as well as between gene mutations. Notably, C9orf72 hexanucleotide repeat expansion positive patients experienced significantly later disease onset than ALS mutation patients. Among SOD1 families, p.I114T positive patients had significantly later onset and longer survival. Our report highlights a unique spectrum of ALS gene frequencies among patients from the Australian population, and further, provides correlations between specific ALS mutations with disease onset and/or duration.
Collapse
Affiliation(s)
- E P McCann
- Faculty of Medicine and Health Sciences, Department of Biomedical Sciences, Macquarie University, Sydney, Australia
| | - K L Williams
- Faculty of Medicine and Health Sciences, Department of Biomedical Sciences, Macquarie University, Sydney, Australia
| | - J A Fifita
- Faculty of Medicine and Health Sciences, Department of Biomedical Sciences, Macquarie University, Sydney, Australia
| | - I S Tarr
- Faculty of Medicine and Health Sciences, Department of Biomedical Sciences, Macquarie University, Sydney, Australia
| | - J O'Connor
- Northcott Neuroscience Laboratory, ANZAC Research Institute, Sydney, Australia
| | - D B Rowe
- Faculty of Medicine and Health Sciences, Department of Biomedical Sciences, Macquarie University, Sydney, Australia
| | - G A Nicholson
- Faculty of Medicine and Health Sciences, Department of Biomedical Sciences, Macquarie University, Sydney, Australia
- Northcott Neuroscience Laboratory, ANZAC Research Institute, Sydney, Australia
- Sydney Medical School, University of Sydney, Sydney, Australia
- Molecular Medicine Laboratory, Concord Hospital, Concord, Australia
| | - I P Blair
- Faculty of Medicine and Health Sciences, Department of Biomedical Sciences, Macquarie University, Sydney, Australia
| |
Collapse
|
38
|
Pavel M, Valle JW, Eriksson B, Rinke A, Caplin M, Chen J, Costa F, Falkerby J, Fazio N, Gorbounova V, de Herder W, Kulke M, Lombard-Bohas C, O'Connor J, Sorbye H, Garcia-Carbonero R. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents. Neuroendocrinology 2017; 105:266-280. [PMID: 28351033 DOI: 10.1159/000471880] [Citation(s) in RCA: 101] [Impact Index Per Article: 14.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/12/2016] [Accepted: 03/21/2017] [Indexed: 12/24/2022]
Abstract
Systemic therapies established in the management of patients with neuroendocrine tumors (NETs) include somatostatin analogs and interferon-α, also referred to as biotherapy. Recent randomized controlled studies have extended the knowledge on the frequency of side effects associated with biotherapy. More recently, novel targeted drugs, such as the mammalian target of rapamycin inhibitor everolimus and the multiple tyrosine kinase inhibitor sunitinib, have been introduced in the management of NETs. Although targeted drugs are generally well tolerated, with most adverse events being of mild to moderate severity and manageable, novel targeted drugs exhibit a distinct adverse event profile that warrants guidance for appropriate diagnostic and therapeutic management. This is particularly important given the widespread and potentially long-term use of everolimus in a broad spectrum of NETs and of sunitinib in pancreatic NETs. This review will focus on the most relevant toxicities associated with biotherapy and novel targeted drugs and on their management. For each drug class indication, administration and dosing schedule, most frequent adverse events, actions and dose adjustments for adverse events as well as their monitoring are presented. This review further covers the evaluation of treatment effect, patient information, drug interactions, and information on pregnancy.
Collapse
Affiliation(s)
- Marianne Pavel
- Department of Hepatology and Gastroenterology, Campus Virchow Klinikum, Charité Universitätsmedizin Berlin, Berlin, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Mair FS, Goldstein P, May C, Angus R, Shiels C, Hibbert D, O'Connor J, Boland A, Roberts C, Haycox A, Capewell S. Patient and provider perspectives on home telecare: Preliminary results from a randomized controlled trial. J Telemed Telecare 2016; 11 Suppl 1:95-7. [PMID: 16036011 DOI: 10.1258/1357633054461976] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
A randomized controlled trial of home telecare for the management of acute exacerbations of chronic obstructive pulmonary disease has been undertaken in the north-west of England. A videophone was used that communicates via the ordinary telephone network. The intervention period for each participant was two weeks. Participants in the telecare arm of the trial were asked to complete logbooks to record their experiences of each telecare encounter. A simple, self-completed, 10–item questionnaire was used that consisted of a Likert scale, ranging from 1 (totally disagree) to 5 (totally agree). Fourteen nurses completed 150 logbooks and 22 patients completed 145 logbooks. These results demonstrate significant differences in perception between patients and their health-care providers with regard to telecare encounters across all the domains addressed. Participating patients consistently demonstrated more positive views of the telecare encounters than their health-care providers.
Collapse
Affiliation(s)
- F S Mair
- University of Liverpool, Liverpool, UK.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Abstract
We analysed the difficulties encountered in recruiting predominantly older patients, suffering from an acute exacerbation of a chronic illness, to a randomized controlled trial of home telecare. Of 653 patients approached for study participation, after full assessment, 80% (519) met the trial eligibility criteria. Of these, 104 (20%) consented to study participation and 415 (80%) refused. A logistic regression model was constructed to examine independent effects of patient factors on probability of trial participation. Only two independent variables were associated with decreased likelihood of consent: increasing age (1 year older: odds ratio [OR] = 0.96); and being on inhaled steroid medication (OR = 0.60). The most common reason for refusal to participate, accounting for almost one-third of respondents, was a stated preference for a face-to-face nurse visiting service rather than a telecare service. Perhaps home telecare services should continue to be targeted at the more stable chronically ill population and not at those suffering from acute illness.
Collapse
Affiliation(s)
- F S Mair
- University of Glasgow, Glasgow, UK.
| | | | | | | | | | | | | | | |
Collapse
|
41
|
Adamson P, An FP, Anghel I, Aurisano A, Balantekin AB, Band HR, Barr G, Bishai M, Blake A, Blyth S, Bock GJ, Bogert D, Cao D, Cao GF, Cao J, Cao SV, Carroll TJ, Castromonte CM, Cen WR, Chan YL, Chang JF, Chang LC, Chang Y, Chen HS, Chen QY, Chen R, Chen SM, Chen Y, Chen YX, Cheng J, Cheng JH, Cheng YP, Cheng ZK, Cherwinka JJ, Childress S, Chu MC, Chukanov A, Coelho JAB, Corwin L, Cronin-Hennessy D, Cummings JP, de Arcos J, De Rijck S, Deng ZY, Devan AV, Devenish NE, Ding XF, Ding YY, Diwan MV, Dolgareva M, Dove J, Dwyer DA, Edwards WR, Escobar CO, Evans JJ, Falk E, Feldman GJ, Flanagan W, Frohne MV, Gabrielyan M, Gallagher HR, Germani S, Gill R, Gomes RA, Gonchar M, Gong GH, Gong H, Goodman MC, Gouffon P, Graf N, Gran R, Grassi M, Grzelak K, Gu WQ, Guan MY, Guo L, Guo RP, Guo XH, Guo Z, Habig A, Hackenburg RW, Hahn SR, Han R, Hans S, Hartnell J, Hatcher R, He M, Heeger KM, Heng YK, Higuera A, Holin A, Hor YK, Hsiung YB, Hu BZ, Hu T, Hu W, Huang EC, Huang HX, Huang J, Huang XT, Huber P, Huo W, Hussain G, Hylen J, Irwin GM, Isvan Z, Jaffe DE, Jaffke P, James C, Jen KL, Jensen D, Jetter S, Ji XL, Ji XP, Jiao JB, Johnson RA, de Jong JK, Joshi J, Kafka T, Kang L, Kasahara SMS, Kettell SH, Kohn S, Koizumi G, Kordosky M, Kramer M, Kreymer A, Kwan KK, Kwok MW, Kwok T, Lang K, Langford TJ, Lau K, Lebanowski L, Lee J, Lee JHC, Lei RT, Leitner R, Leung JKC, Li C, Li DJ, Li F, Li GS, Li QJ, Li S, Li SC, Li WD, Li XN, Li YF, Li ZB, Liang H, Lin CJ, Lin GL, Lin S, Lin SK, Lin YC, Ling JJ, Link JM, Litchfield PJ, Littenberg L, Littlejohn BR, Liu DW, Liu JC, Liu JL, Loh CW, Lu C, Lu HQ, Lu JS, Lucas P, Luk KB, Lv Z, Ma QM, Ma XB, Ma XY, Ma YQ, Malyshkin Y, Mann WA, Marshak ML, Martinez Caicedo DA, Mayer N, McDonald KT, McGivern C, McKeown RD, Medeiros MM, Mehdiyev R, Meier JR, Messier MD, Miller WH, Mishra SR, Mitchell I, Mooney M, Moore CD, Mualem L, Musser J, Nakajima Y, Naples D, Napolitano J, Naumov D, Naumova E, Nelson JK, Newman HB, Ngai HY, Nichol RJ, Ning Z, Nowak JA, O'Connor J, Ochoa-Ricoux JP, Olshevskiy A, Orchanian M, Pahlka RB, Paley J, Pan HR, Park J, Patterson RB, Patton S, Pawloski G, Pec V, Peng JC, Perch A, Pfützner MM, Phan DD, Phan-Budd S, Pinsky L, Plunkett RK, Poonthottathil N, Pun CSJ, Qi FZ, Qi M, Qian X, Qiu X, Radovic A, Raper N, Rebel B, Ren J, Rosenfeld C, Rosero R, Roskovec B, Ruan XC, Rubin HA, Sail P, Sanchez MC, Schneps J, Schreckenberger A, Schreiner P, Sharma R, Moed Sher S, Sousa A, Steiner H, Sun GX, Sun JL, Tagg N, Talaga RL, Tang W, Taychenachev D, Thomas J, Thomson MA, Tian X, Timmons A, Todd J, Tognini SC, Toner R, Torretta D, Treskov K, Tsang KV, Tull CE, Tzanakos G, Urheim J, Vahle P, Viaux N, Viren B, Vorobel V, Wang CH, Wang M, Wang NY, Wang RG, Wang W, Wang X, Wang YF, Wang Z, Wang ZM, Webb RC, Weber A, Wei HY, Wen LJ, Whisnant K, White C, Whitehead L, Whitehead LH, Wise T, Wojcicki SG, Wong HLH, Wong SCF, Worcester E, Wu CH, Wu Q, Wu WJ, Xia DM, Xia JK, Xing ZZ, Xu JL, Xu JY, Xu Y, Xue T, Yang CG, Yang H, Yang L, Yang MS, Yang MT, Ye M, Ye Z, Yeh M, Young BL, Yu ZY, Zeng S, Zhan L, Zhang C, Zhang HH, Zhang JW, Zhang QM, Zhang XT, Zhang YM, Zhang YX, Zhang ZJ, Zhang ZP, Zhang ZY, Zhao J, Zhao QW, Zhao YB, Zhong WL, Zhou L, Zhou N, Zhuang HL, Zou JH. Limits on Active to Sterile Neutrino Oscillations from Disappearance Searches in the MINOS, Daya Bay, and Bugey-3 Experiments. Phys Rev Lett 2016; 117:151801. [PMID: 27768356 DOI: 10.1103/physrevlett.117.151801] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/06/2016] [Indexed: 06/06/2023]
Abstract
Searches for a light sterile neutrino have been performed independently by the MINOS and the Daya Bay experiments using the muon (anti)neutrino and electron antineutrino disappearance channels, respectively. In this Letter, results from both experiments are combined with those from the Bugey-3 reactor neutrino experiment to constrain oscillations into light sterile neutrinos. The three experiments are sensitive to complementary regions of parameter space, enabling the combined analysis to probe regions allowed by the Liquid Scintillator Neutrino Detector (LSND) and MiniBooNE experiments in a minimally extended four-neutrino flavor framework. Stringent limits on sin^{2}2θ_{μe} are set over 6 orders of magnitude in the sterile mass-squared splitting Δm_{41}^{2}. The sterile-neutrino mixing phase space allowed by the LSND and MiniBooNE experiments is excluded for Δm_{41}^{2}<0.8 eV^{2} at 95% CL_{s}.
Collapse
Affiliation(s)
- P Adamson
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - F P An
- Institute of Modern Physics, East China University of Science and Technology, Shanghai
| | - I Anghel
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011 USA
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - A Aurisano
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - A B Balantekin
- Physics Department, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - H R Band
- Department of Physics, Yale University, New Haven, Connecticut 06520, USA
| | - G Barr
- Subdepartment of Particle Physics, University of Oxford, Oxford OX1 3RH, United Kingdom
| | - M Bishai
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - A Blake
- Cavendish Laboratory, University of Cambridge, Cambridge CB3 0HE, United Kingdom
- Lancaster University, Lancaster, LA1 4YB, United Kingdom
| | - S Blyth
- Department of Physics, National Taiwan University, Taipei
- National United University, Miao-Li
| | - G J Bock
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - D Bogert
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - D Cao
- Nanjing University, Nanjing
| | - G F Cao
- Institute of High Energy Physics, Beijing
| | - J Cao
- Institute of High Energy Physics, Beijing
| | - S V Cao
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - T J Carroll
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - C M Castromonte
- Instituto de Física, Universidade Federal de Goiás, 74690-900, Goiânia, GO, Brazil
| | - W R Cen
- Institute of High Energy Physics, Beijing
| | - Y L Chan
- Chinese University of Hong Kong, Hong Kong
| | - J F Chang
- Institute of High Energy Physics, Beijing
| | - L C Chang
- Institute of Physics, National Chiao-Tung University, Hsinchu
| | - Y Chang
- National United University, Miao-Li
| | - H S Chen
- Institute of High Energy Physics, Beijing
| | | | - R Chen
- School of Physics and Astronomy, University of Manchester, Manchester M13 9PL, United Kingdom
| | - S M Chen
- Department of Engineering Physics, Tsinghua University, Beijing
| | - Y Chen
- Shenzhen University, Shenzhen
| | - Y X Chen
- North China Electric Power University, Beijing
| | | | - J-H Cheng
- Institute of Physics, National Chiao-Tung University, Hsinchu
| | - Y P Cheng
- Institute of High Energy Physics, Beijing
| | - Z K Cheng
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - J J Cherwinka
- Physics Department, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - S Childress
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - M C Chu
- Chinese University of Hong Kong, Hong Kong
| | - A Chukanov
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - J A B Coelho
- Physics Department, Tufts University, Medford, Massachusetts 02155, USA
| | - L Corwin
- Indiana University, Bloomington, Indiana 47405, USA
| | | | | | - J de Arcos
- Department of Physics, Illinois Institute of Technology, Chicago, Illinois 60616, USA
| | - S De Rijck
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - Z Y Deng
- Institute of High Energy Physics, Beijing
| | - A V Devan
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
| | - N E Devenish
- Department of Physics and Astronomy, University of Sussex, Falmer, Brighton BN1 9QH, United Kingdom
| | - X F Ding
- Institute of High Energy Physics, Beijing
| | - Y Y Ding
- Institute of High Energy Physics, Beijing
| | - M V Diwan
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - M Dolgareva
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - J Dove
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA
| | - D A Dwyer
- Lawrence Berkeley National Laboratory, Berkeley, California, 94720 USA
| | - W R Edwards
- Lawrence Berkeley National Laboratory, Berkeley, California, 94720 USA
| | - C O Escobar
- Universidade Estadual de Campinas, IFGW, CP 6165, 13083-970, Campinas, SP, Brazil
| | - J J Evans
- School of Physics and Astronomy, University of Manchester, Manchester M13 9PL, United Kingdom
| | - E Falk
- Department of Physics and Astronomy, University of Sussex, Falmer, Brighton BN1 9QH, United Kingdom
| | - G J Feldman
- Department of Physics, Harvard University, Cambridge, Massachusetts 02138, USA
| | - W Flanagan
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - M V Frohne
- Holy Cross College, Notre Dame, Indiana 46556, USA
| | - M Gabrielyan
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - H R Gallagher
- Physics Department, Tufts University, Medford, Massachusetts 02155, USA
| | - S Germani
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - R Gill
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - R A Gomes
- Instituto de Física, Universidade Federal de Goiás, 74690-900, Goiânia, GO, Brazil
| | - M Gonchar
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - G H Gong
- Department of Engineering Physics, Tsinghua University, Beijing
| | - H Gong
- Department of Engineering Physics, Tsinghua University, Beijing
| | - M C Goodman
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - P Gouffon
- Instituto de Física, Universidade de São Paulo, CP 66318, 05315-970, São Paulo, SP, Brazil
| | - N Graf
- Department of Physics and Astronomy, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA
| | - R Gran
- Department of Physics, University of Minnesota Duluth, Duluth, Minnesota 55812, USA
| | - M Grassi
- Institute of High Energy Physics, Beijing
| | - K Grzelak
- Department of Physics, University of Warsaw, PL-02-093 Warsaw, Poland
| | - W Q Gu
- Department of Physics and Astronomy, Shanghai Jiao Tong University, Shanghai Laboratory for Particle Physics and Cosmology, Shanghai
| | - M Y Guan
- Institute of High Energy Physics, Beijing
| | - L Guo
- Department of Engineering Physics, Tsinghua University, Beijing
| | - R P Guo
- Institute of High Energy Physics, Beijing
| | - X H Guo
- Beijing Normal University, Beijing
| | - Z Guo
- Department of Engineering Physics, Tsinghua University, Beijing
| | - A Habig
- Department of Physics, University of Minnesota Duluth, Duluth, Minnesota 55812, USA
| | - R W Hackenburg
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - S R Hahn
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - R Han
- North China Electric Power University, Beijing
| | - S Hans
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - J Hartnell
- Department of Physics and Astronomy, University of Sussex, Falmer, Brighton BN1 9QH, United Kingdom
| | - R Hatcher
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - M He
- Institute of High Energy Physics, Beijing
| | - K M Heeger
- Department of Physics, Yale University, New Haven, Connecticut 06520, USA
| | - Y K Heng
- Institute of High Energy Physics, Beijing
| | - A Higuera
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - A Holin
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - Y K Hor
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia 24061, USA
| | - Y B Hsiung
- Department of Physics, National Taiwan University, Taipei
| | - B Z Hu
- Department of Physics, National Taiwan University, Taipei
| | - T Hu
- Institute of High Energy Physics, Beijing
| | - W Hu
- Institute of High Energy Physics, Beijing
| | - E C Huang
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA
| | - H X Huang
- China Institute of Atomic Energy, Beijing
| | - J Huang
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | | | - P Huber
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia 24061, USA
| | - W Huo
- University of Science and Technology of China, Hefei
| | - G Hussain
- Department of Engineering Physics, Tsinghua University, Beijing
| | - J Hylen
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - G M Irwin
- Department of Physics, Stanford University, Stanford, California 94305, USA
| | - Z Isvan
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - D E Jaffe
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - P Jaffke
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia 24061, USA
| | - C James
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - K L Jen
- Institute of Physics, National Chiao-Tung University, Hsinchu
| | - D Jensen
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - S Jetter
- Institute of High Energy Physics, Beijing
| | - X L Ji
- Institute of High Energy Physics, Beijing
| | - X P Ji
- Department of Engineering Physics, Tsinghua University, Beijing
- School of Physics, Nankai University, Tianjin
| | | | - R A Johnson
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - J K de Jong
- Subdepartment of Particle Physics, University of Oxford, Oxford OX1 3RH, United Kingdom
| | - J Joshi
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - T Kafka
- Physics Department, Tufts University, Medford, Massachusetts 02155, USA
| | - L Kang
- Dongguan University of Technology, Dongguan
| | - S M S Kasahara
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - S H Kettell
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - S Kohn
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - G Koizumi
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - M Kordosky
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
| | - M Kramer
- Lawrence Berkeley National Laboratory, Berkeley, California, 94720 USA
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - A Kreymer
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - K K Kwan
- Chinese University of Hong Kong, Hong Kong
| | - M W Kwok
- Chinese University of Hong Kong, Hong Kong
| | - T Kwok
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong
| | - K Lang
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - T J Langford
- Department of Physics, Yale University, New Haven, Connecticut 06520, USA
| | - K Lau
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - L Lebanowski
- Department of Engineering Physics, Tsinghua University, Beijing
| | - J Lee
- Lawrence Berkeley National Laboratory, Berkeley, California, 94720 USA
| | - J H C Lee
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong
| | - R T Lei
- Dongguan University of Technology, Dongguan
| | - R Leitner
- Charles University, Faculty of Mathematics and Physics, Prague, Czech Republic
| | - J K C Leung
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong
| | - C Li
- Shandong University, Jinan
| | - D J Li
- University of Science and Technology of China, Hefei
| | - F Li
- Institute of High Energy Physics, Beijing
| | - G S Li
- Department of Physics and Astronomy, Shanghai Jiao Tong University, Shanghai Laboratory for Particle Physics and Cosmology, Shanghai
| | - Q J Li
- Institute of High Energy Physics, Beijing
| | - S Li
- Dongguan University of Technology, Dongguan
| | - S C Li
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia 24061, USA
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong
| | - W D Li
- Institute of High Energy Physics, Beijing
| | - X N Li
- Institute of High Energy Physics, Beijing
| | - Y F Li
- Institute of High Energy Physics, Beijing
| | - Z B Li
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - H Liang
- University of Science and Technology of China, Hefei
| | - C J Lin
- Lawrence Berkeley National Laboratory, Berkeley, California, 94720 USA
| | - G L Lin
- Institute of Physics, National Chiao-Tung University, Hsinchu
| | - S Lin
- Dongguan University of Technology, Dongguan
| | - S K Lin
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - Y-C Lin
- Department of Physics, National Taiwan University, Taipei
| | - J J Ling
- Brookhaven National Laboratory, Upton, New York 11973, USA
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - J M Link
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia 24061, USA
| | - P J Litchfield
- University of Minnesota, Minneapolis, Minnesota 55455, USA
- Rutherford Appleton Laboratory, Science and Technology Facilities Council, Didcot, OX11 0QX, United Kingdom
| | - L Littenberg
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - B R Littlejohn
- Department of Physics, Illinois Institute of Technology, Chicago, Illinois 60616, USA
| | - D W Liu
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - J C Liu
- Institute of High Energy Physics, Beijing
| | - J L Liu
- Department of Physics and Astronomy, Shanghai Jiao Tong University, Shanghai Laboratory for Particle Physics and Cosmology, Shanghai
| | | | - C Lu
- Joseph Henry Laboratories, Princeton University, Princeton, New Jersey 08544, USA
| | - H Q Lu
- Institute of High Energy Physics, Beijing
| | - J S Lu
- Institute of High Energy Physics, Beijing
| | - P Lucas
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - K B Luk
- Lawrence Berkeley National Laboratory, Berkeley, California, 94720 USA
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - Z Lv
- Xi'an Jiaotong University, Xi'an
| | - Q M Ma
- Institute of High Energy Physics, Beijing
| | - X B Ma
- North China Electric Power University, Beijing
| | - X Y Ma
- Institute of High Energy Physics, Beijing
| | - Y Q Ma
- Institute of High Energy Physics, Beijing
| | - Y Malyshkin
- Instituto de Física, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - W A Mann
- Physics Department, Tufts University, Medford, Massachusetts 02155, USA
| | - M L Marshak
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - D A Martinez Caicedo
- Department of Physics, Illinois Institute of Technology, Chicago, Illinois 60616, USA
| | - N Mayer
- Physics Department, Tufts University, Medford, Massachusetts 02155, USA
| | - K T McDonald
- Joseph Henry Laboratories, Princeton University, Princeton, New Jersey 08544, USA
| | - C McGivern
- Department of Physics and Astronomy, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA
| | - R D McKeown
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
- Lauritsen Laboratory, California Institute of Technology, Pasadena, California 91125, USA
| | - M M Medeiros
- Instituto de Física, Universidade Federal de Goiás, 74690-900, Goiânia, GO, Brazil
| | - R Mehdiyev
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - J R Meier
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - M D Messier
- Indiana University, Bloomington, Indiana 47405, USA
| | - W H Miller
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - S R Mishra
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - I Mitchell
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - M Mooney
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - C D Moore
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - L Mualem
- Lauritsen Laboratory, California Institute of Technology, Pasadena, California 91125, USA
| | - J Musser
- Indiana University, Bloomington, Indiana 47405, USA
| | - Y Nakajima
- Lawrence Berkeley National Laboratory, Berkeley, California, 94720 USA
| | - D Naples
- Department of Physics and Astronomy, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA
| | - J Napolitano
- Department of Physics, College of Science and Technology, Temple University, Philadelphia, Pennsylvania 19122, USA
| | - D Naumov
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - E Naumova
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - J K Nelson
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
| | - H B Newman
- Lauritsen Laboratory, California Institute of Technology, Pasadena, California 91125, USA
| | - H Y Ngai
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong
| | - R J Nichol
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - Z Ning
- Institute of High Energy Physics, Beijing
| | - J A Nowak
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - J O'Connor
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - J P Ochoa-Ricoux
- Instituto de Física, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - A Olshevskiy
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - M Orchanian
- Lauritsen Laboratory, California Institute of Technology, Pasadena, California 91125, USA
| | - R B Pahlka
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - J Paley
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - H-R Pan
- Department of Physics, National Taiwan University, Taipei
| | - J Park
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia 24061, USA
| | - R B Patterson
- Lauritsen Laboratory, California Institute of Technology, Pasadena, California 91125, USA
| | - S Patton
- Lawrence Berkeley National Laboratory, Berkeley, California, 94720 USA
| | - G Pawloski
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - V Pec
- Charles University, Faculty of Mathematics and Physics, Prague, Czech Republic
| | - J C Peng
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA
| | - A Perch
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - M M Pfützner
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - D D Phan
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - S Phan-Budd
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - L Pinsky
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - R K Plunkett
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - N Poonthottathil
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - C S J Pun
- Department of Physics, The University of Hong Kong, Pokfulam, Hong Kong
| | - F Z Qi
- Institute of High Energy Physics, Beijing
| | - M Qi
- Nanjing University, Nanjing
| | - X Qian
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - X Qiu
- Department of Physics, Stanford University, Stanford, California 94305, USA
| | - A Radovic
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
| | - N Raper
- Department of Physics, Applied Physics, and Astronomy, Rensselaer Polytechnic Institute, Troy, New York 12180, USA
| | - B Rebel
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - J Ren
- China Institute of Atomic Energy, Beijing
| | - C Rosenfeld
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - R Rosero
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - B Roskovec
- Charles University, Faculty of Mathematics and Physics, Prague, Czech Republic
| | - X C Ruan
- China Institute of Atomic Energy, Beijing
| | - H A Rubin
- Department of Physics, Illinois Institute of Technology, Chicago, Illinois 60616, USA
| | - P Sail
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - M C Sanchez
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011 USA
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - J Schneps
- Physics Department, Tufts University, Medford, Massachusetts 02155, USA
| | - A Schreckenberger
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - P Schreiner
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - R Sharma
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - S Moed Sher
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - A Sousa
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - H Steiner
- Lawrence Berkeley National Laboratory, Berkeley, California, 94720 USA
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - G X Sun
- Institute of High Energy Physics, Beijing
| | - J L Sun
- China General Nuclear Power Group
| | - N Tagg
- Otterbein University, Westerville, Ohio 43081, USA
| | - R L Talaga
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - W Tang
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - D Taychenachev
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - J Thomas
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - M A Thomson
- Cavendish Laboratory, University of Cambridge, Cambridge CB3 0HE, United Kingdom
| | - X Tian
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - A Timmons
- School of Physics and Astronomy, University of Manchester, Manchester M13 9PL, United Kingdom
| | - J Todd
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - S C Tognini
- Instituto de Física, Universidade Federal de Goiás, 74690-900, Goiânia, GO, Brazil
| | - R Toner
- Department of Physics, Harvard University, Cambridge, Massachusetts 02138, USA
| | - D Torretta
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - K Treskov
- Joint Institute for Nuclear Research, Dubna, Moscow Region
| | - K V Tsang
- Lawrence Berkeley National Laboratory, Berkeley, California, 94720 USA
| | - C E Tull
- Lawrence Berkeley National Laboratory, Berkeley, California, 94720 USA
| | - G Tzanakos
- Department of Physics, University of Athens, GR-15771 Athens, Greece
| | - J Urheim
- Indiana University, Bloomington, Indiana 47405, USA
| | - P Vahle
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
| | - N Viaux
- Instituto de Física, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - B Viren
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - V Vorobel
- Charles University, Faculty of Mathematics and Physics, Prague, Czech Republic
| | - C H Wang
- National United University, Miao-Li
| | - M Wang
- Shandong University, Jinan
| | - N Y Wang
- Beijing Normal University, Beijing
| | - R G Wang
- Institute of High Energy Physics, Beijing
| | - W Wang
- Sun Yat-Sen (Zhongshan) University, Guangzhou
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
| | - X Wang
- College of Electronic Science and Engineering, National University of Defense Technology, Changsha
| | - Y F Wang
- Institute of High Energy Physics, Beijing
| | - Z Wang
- Institute of High Energy Physics, Beijing
| | - Z M Wang
- Institute of High Energy Physics, Beijing
| | - R C Webb
- Physics Department, Texas A&M University, College Station, Texas 77843, USA
| | - A Weber
- Subdepartment of Particle Physics, University of Oxford, Oxford OX1 3RH, United Kingdom
- Rutherford Appleton Laboratory, Science and Technology Facilities Council, Didcot, OX11 0QX, United Kingdom
| | - H Y Wei
- Department of Engineering Physics, Tsinghua University, Beijing
| | - L J Wen
- Institute of High Energy Physics, Beijing
| | - K Whisnant
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011 USA
| | - C White
- Department of Physics, Illinois Institute of Technology, Chicago, Illinois 60616, USA
| | - L Whitehead
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - L H Whitehead
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - T Wise
- Physics Department, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - S G Wojcicki
- Department of Physics, Stanford University, Stanford, California 94305, USA
| | - H L H Wong
- Lawrence Berkeley National Laboratory, Berkeley, California, 94720 USA
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - S C F Wong
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - E Worcester
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - C-H Wu
- Institute of Physics, National Chiao-Tung University, Hsinchu
| | - Q Wu
- Shandong University, Jinan
| | - W J Wu
- Institute of High Energy Physics, Beijing
| | - D M Xia
- Chongqing University, Chongqing
| | - J K Xia
- Institute of High Energy Physics, Beijing
| | - Z Z Xing
- Institute of High Energy Physics, Beijing
| | - J L Xu
- Institute of High Energy Physics, Beijing
| | - J Y Xu
- Chinese University of Hong Kong, Hong Kong
| | - Y Xu
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - T Xue
- Department of Engineering Physics, Tsinghua University, Beijing
| | - C G Yang
- Institute of High Energy Physics, Beijing
| | - H Yang
- Nanjing University, Nanjing
| | - L Yang
- Dongguan University of Technology, Dongguan
| | - M S Yang
- Institute of High Energy Physics, Beijing
| | | | - M Ye
- Institute of High Energy Physics, Beijing
| | - Z Ye
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - M Yeh
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - B L Young
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011 USA
| | - Z Y Yu
- Institute of High Energy Physics, Beijing
| | - S Zeng
- Institute of High Energy Physics, Beijing
| | - L Zhan
- Institute of High Energy Physics, Beijing
| | - C Zhang
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - H H Zhang
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | - J W Zhang
- Institute of High Energy Physics, Beijing
| | | | - X T Zhang
- Institute of High Energy Physics, Beijing
| | - Y M Zhang
- Sun Yat-Sen (Zhongshan) University, Guangzhou
| | | | - Z J Zhang
- Dongguan University of Technology, Dongguan
| | - Z P Zhang
- University of Science and Technology of China, Hefei
| | - Z Y Zhang
- Institute of High Energy Physics, Beijing
| | - J Zhao
- Institute of High Energy Physics, Beijing
| | - Q W Zhao
- Institute of High Energy Physics, Beijing
| | - Y B Zhao
- Institute of High Energy Physics, Beijing
| | - W L Zhong
- Institute of High Energy Physics, Beijing
| | - L Zhou
- Institute of High Energy Physics, Beijing
| | - N Zhou
- University of Science and Technology of China, Hefei
| | - H L Zhuang
- Institute of High Energy Physics, Beijing
| | - J H Zou
- Institute of High Energy Physics, Beijing
| |
Collapse
|
42
|
Adamson P, Anghel I, Aurisano A, Barr G, Bishai M, Blake A, Bock GJ, Bogert D, Cao SV, Carroll TJ, Castromonte CM, Chen R, Childress S, Coelho JAB, Corwin L, Cronin-Hennessy D, de Jong JK, De Rijck S, Devan AV, Devenish NE, Diwan MV, Escobar CO, Evans JJ, Falk E, Feldman GJ, Flanagan W, Frohne MV, Gabrielyan M, Gallagher HR, Germani S, Gomes RA, Goodman MC, Gouffon P, Graf N, Gran R, Grzelak K, Habig A, Hahn SR, Hartnell J, Hatcher R, Holin A, Huang J, Hylen J, Irwin GM, Isvan Z, James C, Jensen D, Kafka T, Kasahara SMS, Koizumi G, Kordosky M, Kreymer A, Lang K, Ling J, Litchfield PJ, Lucas P, Mann WA, Marshak ML, Mayer N, McGivern C, Medeiros MM, Mehdiyev R, Meier JR, Messier MD, Miller WH, Mishra SR, Moed Sher S, Moore CD, Mualem L, Musser J, Naples D, Nelson JK, Newman HB, Nichol RJ, Nowak JA, O'Connor J, Orchanian M, Pahlka RB, Paley J, Patterson RB, Pawloski G, Perch A, Pfützner MM, Phan DD, Phan-Budd S, Plunkett RK, Poonthottathil N, Qiu X, Radovic A, Rebel B, Rosenfeld C, Rubin HA, Sail P, Sanchez MC, Schneps J, Schreckenberger A, Schreiner P, Sharma R, Sousa A, Tagg N, Talaga RL, Thomas J, Thomson MA, Tian X, Timmons A, Todd J, Tognini SC, Toner R, Torretta D, Tzanakos G, Urheim J, Vahle P, Viren B, Weber A, Webb RC, White C, Whitehead L, Whitehead LH, Wojcicki SG, Zwaska R. Search for Sterile Neutrinos Mixing with Muon Neutrinos in MINOS. Phys Rev Lett 2016; 117:151803. [PMID: 27768323 DOI: 10.1103/physrevlett.117.151803] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/06/2016] [Indexed: 06/06/2023]
Abstract
We report results of a search for oscillations involving a light sterile neutrino over distances of 1.04 and 735 km in a ν_{μ}-dominated beam with a peak energy of 3 GeV. The data, from an exposure of 10.56×10^{20} protons on target, are analyzed using a phenomenological model with one sterile neutrino. We constrain the mixing parameters θ_{24} and Δm_{41}^{2} and set limits on parameters of the four-dimensional Pontecorvo-Maki-Nakagawa-Sakata matrix, |U_{μ4}|^{2} and |U_{τ4}|^{2}, under the assumption that mixing between ν_{e} and ν_{s} is negligible (|U_{e4}|^{2}=0). No evidence for ν_{μ}→ν_{s} transitions is found and we set a world-leading limit on θ_{24} for values of Δm_{41}^{2}≲1 eV^{2}.
Collapse
Affiliation(s)
- P Adamson
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - I Anghel
- Argonne National Laboratory, Argonne, Illinois 60439, USA
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011 USA
| | - A Aurisano
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - G Barr
- Subdepartment of Particle Physics, University of Oxford, Oxford OX1 3RH, United Kingdom
| | - M Bishai
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - A Blake
- Cavendish Laboratory, University of Cambridge, Cambridge CB3 0HE, United Kingdom
- Lancaster University, Lancaster, LA1 4YB, United Kingdom
| | - G J Bock
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - D Bogert
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - S V Cao
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - T J Carroll
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - C M Castromonte
- Instituto de Física, Universidade Federal de Goiás, 74690-900 Goiânia, Goiás, Brazil
| | - R Chen
- School of Physics and Astronomy, University of Manchester, Manchester M13 9PL, United Kingdom
| | - S Childress
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - J A B Coelho
- Physics Department, Tufts University, Medford, Massachusetts 02155, USA
| | - L Corwin
- Indiana University, Bloomington, Indiana 47405, USA
| | | | - J K de Jong
- Subdepartment of Particle Physics, University of Oxford, Oxford OX1 3RH, United Kingdom
| | - S De Rijck
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - A V Devan
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
| | - N E Devenish
- Department of Physics and Astronomy, University of Sussex, Falmer, Brighton BN1 9QH, United Kingdom
| | - M V Diwan
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - C O Escobar
- Universidade Estadual de Campinas, IFGW, CP 6165, 13083-970 Campinas, São Paulo, Brazil
| | - J J Evans
- School of Physics and Astronomy, University of Manchester, Manchester M13 9PL, United Kingdom
| | - E Falk
- Department of Physics and Astronomy, University of Sussex, Falmer, Brighton BN1 9QH, United Kingdom
| | - G J Feldman
- Department of Physics, Harvard University, Cambridge, Massachusetts 02138, USA
| | - W Flanagan
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - M V Frohne
- Holy Cross College, Notre Dame, Indiana 46556, USA
| | - M Gabrielyan
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - H R Gallagher
- Physics Department, Tufts University, Medford, Massachusetts 02155, USA
| | - S Germani
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - R A Gomes
- Instituto de Física, Universidade Federal de Goiás, 74690-900 Goiânia, Goiás, Brazil
| | - M C Goodman
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - P Gouffon
- Instituto de Física, Universidade de São Paulo, CP 66318, 05315-970 São Paulo, São Paulo, Brazil
| | - N Graf
- Department of Physics and Astronomy, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA
| | - R Gran
- Department of Physics, University of Minnesota Duluth, Duluth, Minnesota 55812, USA
| | - K Grzelak
- Department of Physics, University of Warsaw, PL-02-093 Warsaw, Poland
| | - A Habig
- Department of Physics, University of Minnesota Duluth, Duluth, Minnesota 55812, USA
| | - S R Hahn
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - J Hartnell
- Department of Physics and Astronomy, University of Sussex, Falmer, Brighton BN1 9QH, United Kingdom
| | - R Hatcher
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - A Holin
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - J Huang
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - J Hylen
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - G M Irwin
- Department of Physics, Stanford University, Stanford, California 94305, USA
| | - Z Isvan
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - C James
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - D Jensen
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - T Kafka
- Physics Department, Tufts University, Medford, Massachusetts 02155, USA
| | - S M S Kasahara
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - G Koizumi
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - M Kordosky
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
| | - A Kreymer
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - K Lang
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - J Ling
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - P J Litchfield
- University of Minnesota, Minneapolis, Minnesota 55455, USA
- Rutherford Appleton Laboratory, Science and Technology Facilities Council, Didcot, OX11 0QX, United Kingdom
| | - P Lucas
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - W A Mann
- Physics Department, Tufts University, Medford, Massachusetts 02155, USA
| | - M L Marshak
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - N Mayer
- Physics Department, Tufts University, Medford, Massachusetts 02155, USA
| | - C McGivern
- Department of Physics and Astronomy, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA
| | - M M Medeiros
- Instituto de Física, Universidade Federal de Goiás, 74690-900 Goiânia, Goiás, Brazil
| | - R Mehdiyev
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - J R Meier
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - M D Messier
- Indiana University, Bloomington, Indiana 47405, USA
| | - W H Miller
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - S R Mishra
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - S Moed Sher
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - C D Moore
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - L Mualem
- Lauritsen Laboratory, California Institute of Technology, Pasadena, California 91125, USA
| | - J Musser
- Indiana University, Bloomington, Indiana 47405, USA
| | - D Naples
- Department of Physics and Astronomy, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA
| | - J K Nelson
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
| | - H B Newman
- Lauritsen Laboratory, California Institute of Technology, Pasadena, California 91125, USA
| | - R J Nichol
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - J A Nowak
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - J O'Connor
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - M Orchanian
- Lauritsen Laboratory, California Institute of Technology, Pasadena, California 91125, USA
| | - R B Pahlka
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - J Paley
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - R B Patterson
- Lauritsen Laboratory, California Institute of Technology, Pasadena, California 91125, USA
| | - G Pawloski
- University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - A Perch
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - M M Pfützner
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - D D Phan
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - S Phan-Budd
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - R K Plunkett
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - N Poonthottathil
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - X Qiu
- Department of Physics, Stanford University, Stanford, California 94305, USA
| | - A Radovic
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
| | - B Rebel
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - C Rosenfeld
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - H A Rubin
- Department of Physics, Illinois Institute of Technology, Chicago, Illinois 60616, USA
| | - P Sail
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - M C Sanchez
- Argonne National Laboratory, Argonne, Illinois 60439, USA
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011 USA
| | - J Schneps
- Physics Department, Tufts University, Medford, Massachusetts 02155, USA
| | - A Schreckenberger
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - P Schreiner
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - R Sharma
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - A Sousa
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - N Tagg
- Otterbein University, Westerville, Ohio 43081, USA
| | - R L Talaga
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - J Thomas
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - M A Thomson
- Cavendish Laboratory, University of Cambridge, Cambridge CB3 0HE, United Kingdom
| | - X Tian
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - A Timmons
- School of Physics and Astronomy, University of Manchester, Manchester M13 9PL, United Kingdom
| | - J Todd
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - S C Tognini
- Instituto de Física, Universidade Federal de Goiás, 74690-900 Goiânia, Goiás, Brazil
| | - R Toner
- Department of Physics, Harvard University, Cambridge, Massachusetts 02138, USA
| | - D Torretta
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - G Tzanakos
- Department of Physics, University of Athens, GR-15771 Athens, Greece
| | - J Urheim
- Indiana University, Bloomington, Indiana 47405, USA
| | - P Vahle
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
| | - B Viren
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - A Weber
- Subdepartment of Particle Physics, University of Oxford, Oxford OX1 3RH, United Kingdom
- Rutherford Appleton Laboratory, Science and Technology Facilities Council, Didcot, OX11 0QX, United Kingdom
| | - R C Webb
- Physics Department, Texas A&M University, College Station, Texas 77843, USA
| | - C White
- Department of Physics, Illinois Institute of Technology, Chicago, Illinois 60616, USA
| | - L Whitehead
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - L H Whitehead
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
| | - S G Wojcicki
- Department of Physics, Stanford University, Stanford, California 94305, USA
| | - R Zwaska
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| |
Collapse
|
43
|
Bianconi F, Bonomo M, Marconi A, Kolliakou A, Stilo SA, Iyegbe C, Gurillo Muñoz P, Homayoun S, Mondelli V, Luzi S, Dazzan P, Prata D, La Cascia C, O'Connor J, David A, Morgan C, Murray RM, Lynskey M, Di Forti M. Differences in cannabis-related experiences between patients with a first episode of psychosis and controls. Psychol Med 2016; 46:995-1003. [PMID: 26670601 DOI: 10.1017/s0033291715002494] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
BACKGROUND Many studies have reported that cannabis use increases the risk of a first episode of psychosis (FEP). However, only a few studies have investigated the nature of cannabis-related experiences in FEP patients, and none has examined whether these experiences are similar in FEP and general populations. The aim of this study was to explore differences in self-reported cannabis experiences between FEP and non-psychotic populations. METHOD A total of 252 subjects, who met International Classification of Diseases (ICD)-10 criteria for FEP, and 217 controls who reported cannabis use were selected from the Genetics and Psychosis (GAP) study. The Medical Research Council Social Schedule and the Cannabis Experience Questionnaire were used to collect sociodemographic data and cannabis use information, respectively. RESULTS Both 'bad' and 'enjoyable' experiences were more commonly reported by FEP subjects than controls. Principal components factor analysis identified four components which explained 62.3% of the variance. Linear regression analysis on the whole sample showed that the type of cannabis used and beliefs about the effect of cannabis on health all contributed to determining the intensity and frequency of experiences. Linear regression analysis on FEP subjects showed that the duration of cannabis use and amount of money spent on cannabis were strongly related to the intensity and frequency of enjoyable experiences in this population. CONCLUSIONS These results suggest a higher sensitivity to cannabis effects among people who have suffered their first psychotic episode; this hypersensitivity results in them reporting both more 'bad' and 'enjoyable' experiences. The greater enjoyment experienced may provide an explanation of why FEP patients are more likely to use cannabis and to continue to use it despite experiencing an exacerbation of their psychotic symptoms.
Collapse
Affiliation(s)
- F Bianconi
- Department of Psychosis Studies,Institute of Psychiatry, Psychology and Neuroscience, King's College London,London,UK
| | - M Bonomo
- Department of Psychosis Studies,Institute of Psychiatry, Psychology and Neuroscience, King's College London,London,UK
| | - A Marconi
- Department of Paediatrics and Child and Adolescent Neuropsychiatry,'Sapienza' University of Rome,Rome,Italy
| | - A Kolliakou
- Biomedical Research Centre Nucleus,King's College London,London,UK
| | - S A Stilo
- Department of Psychosis Studies,Institute of Psychiatry, Psychology and Neuroscience, King's College London,London,UK
| | - C Iyegbe
- Department of Psychosis Studies,Institute of Psychiatry, Psychology and Neuroscience, King's College London,London,UK
| | | | - S Homayoun
- Department of Psychosis Studies,Institute of Psychiatry, Psychology and Neuroscience, King's College London,London,UK
| | - V Mondelli
- Department of Psychosis Studies,Institute of Psychiatry, Psychology and Neuroscience, King's College London,London,UK
| | - S Luzi
- Department of Psychosis Studies,Institute of Psychiatry, Psychology and Neuroscience, King's College London,London,UK
| | - P Dazzan
- Department of Psychosis Studies,Institute of Psychiatry, Psychology and Neuroscience, King's College London,London,UK
| | - D Prata
- Department of Neuroimaging,Institute of Psychiatry, Psychology and Neuroscience, King's College London,London,UK
| | - C La Cascia
- Department of Experimental Biomedicine and Clinical Neuroscience,University of Palermo,Palermo,Italy
| | - J O'Connor
- Department of Psychosis Studies,Institute of Psychiatry, Psychology and Neuroscience, King's College London,London,UK
| | - A David
- Department of Psychosis Studies,Institute of Psychiatry, Psychology and Neuroscience, King's College London,London,UK
| | - C Morgan
- Department of Psychosis Studies,Institute of Psychiatry, Psychology and Neuroscience, King's College London,London,UK
| | - R M Murray
- Department of Psychosis Studies,Institute of Psychiatry, Psychology and Neuroscience, King's College London,London,UK
| | - M Lynskey
- Addiction Department,Institute of Psychiatry, Psychology and Neuroscience, King's College London,London,UK
| | - M Di Forti
- Department of Psychosis Studies,Institute of Psychiatry, Psychology and Neuroscience, King's College London,London,UK
| |
Collapse
|
44
|
Solano Fonseca R, Mahesula S, Apple DM, Raghunathan R, Dugan A, Cardona A, O'Connor J, Kokovay E. Neurogenic Niche Microglia Undergo Positional Remodeling and Progressive Activation Contributing to Age-Associated Reductions in Neurogenesis. Stem Cells Dev 2016; 25:542-55. [PMID: 26857912 DOI: 10.1089/scd.2015.0319] [Citation(s) in RCA: 70] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
Neural stem cells (NSCs) exist throughout life in the ventricular-subventricular zone (V-SVZ) of the mammalian forebrain. During aging NSC function is diminished through an unclear mechanism. In this study, we establish microglia, the immune cells of the brain, as integral niche cells within the V-SVZ that undergo age-associated repositioning in the V-SVZ. Microglia become activated early before NSC deficits during aging resulting in an antineurogenic microenvironment due to increased inflammatory cytokine secretion. These age-associated changes were not observed in non-neurogenic brain regions, suggesting V-SVZ microglia are specialized. Using a sustained inflammatory model in young adult mice, we induced microglia activation and inflammation that was accompanied by reduced NSC proliferation in the V-SVZ. Furthermore, in vitro studies revealed secreted factors from activated microglia reduced proliferation and neuron production compared to secreted factors from resting microglia. Our results suggest that age-associated chronic inflammation contributes to declines in NSC function within the aging neurogenic niche.
Collapse
Affiliation(s)
- Rene Solano Fonseca
- 1 Department of Cellular and Structural Biology, University of Texas Health Science Center at San Antonio , San Antonio, Texas.,2 Barshop Institute for Longevity and Aging Studies , San Antonio, Texas
| | - Swetha Mahesula
- 1 Department of Cellular and Structural Biology, University of Texas Health Science Center at San Antonio , San Antonio, Texas
| | - Deana M Apple
- 1 Department of Cellular and Structural Biology, University of Texas Health Science Center at San Antonio , San Antonio, Texas.,2 Barshop Institute for Longevity and Aging Studies , San Antonio, Texas
| | - Rekha Raghunathan
- 3 Molecular and Translational Medicine, Boston University , Boston, Massachusetts
| | - Allison Dugan
- 4 Department of Pharmacology, University of Texas Health Science Center at San Antonio , San Antonio, Texas
| | - Astrid Cardona
- 5 Department of Biology, University of Texas at San Antonio , San Antonio, Texas
| | - Jason O'Connor
- 4 Department of Pharmacology, University of Texas Health Science Center at San Antonio , San Antonio, Texas
| | - Erzsebet Kokovay
- 1 Department of Cellular and Structural Biology, University of Texas Health Science Center at San Antonio , San Antonio, Texas.,2 Barshop Institute for Longevity and Aging Studies , San Antonio, Texas
| |
Collapse
|
45
|
Niederle B, Pape UF, Costa F, Gross D, Kelestimur F, Knigge U, Öberg K, Pavel M, Perren A, Toumpanakis C, O'Connor J, O'Toole D, Krenning E, Reed N, Kianmanesh R. ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum. Neuroendocrinology 2016; 103:125-38. [PMID: 26758972 DOI: 10.1159/000443170] [Citation(s) in RCA: 291] [Impact Index Per Article: 36.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- B Niederle
- Department of Surgery, Medical University of Vienna, Vienna, Austria
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Pape UF, Niederle B, Costa F, Gross D, Kelestimur F, Kianmanesh R, Knigge U, Öberg K, Pavel M, Perren A, Toumpanakis C, O'Connor J, Krenning E, Reed N, O'Toole D. ENETS Consensus Guidelines for Neuroendocrine Neoplasms of the Appendix (Excluding Goblet Cell Carcinomas). Neuroendocrinology 2016; 103:144-52. [PMID: 26730583 DOI: 10.1159/000443165] [Citation(s) in RCA: 154] [Impact Index Per Article: 19.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- U-F Pape
- Department of Hepatology and Gastroenterology, Campus Virchow Klinikum, Charitx00E9; Universitx00E4;tsmedizin Berlin, Berlin, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Tanner R, Twomey M, Maher MM, Fitzgerald E, O'Connor J. A Rare Cause of Testicular Pain: Thrombosis of the Pampiniform Plexus. Ir Med J 2016; 109:347-348. [PMID: 26904794] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Testicular pain is a common presentation in the emergency department. The cause includes a wide array of differentials. This report highlights a case of thrombosis of the pampiniform plexus as a rare cause of testicular pain. Doppler ultrasound should be the first line investigation. Symptomatic relief with anti-inflammatory medication should be sufficient for management.
Collapse
|
48
|
Soliman EZ, Sharma S, Arastéh K, Wohl D, Achhra A, Tambussi G, O'Connor J, Stein JH, Duprez DA, Neaton JD, Phillips A. Baseline cardiovascular risk in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015; 16 Suppl 1:46-54. [PMID: 25711323 DOI: 10.1111/hiv.12233] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
OBJECTIVES The Strategic Timing of AntiRetroviral Treatment (START) trial has recruited antiretroviral-naïve individuals with high CD4 cell counts from all regions of the world. We describe the distribution of cardiovascular disease (CVD) risk factors, overall and by geographical region, at study baseline. METHODS The distribution of CVD risk factors was assessed and compared by geographical region among START participants who had a baseline electrocardiogram (n = 4019; North America, 11%; Europe/Australia/Israel, 36%; South America, 26%; Asia, 4%; Africa, 23%; median age 36 years; 26% female). RESULTS About 58.3% (n = 2344) of the participants had at least one CVD risk factor and 18.9% (n = 761) had two or more. The most common CVD risk factors were current smoking (32%), hypertension (19.3%) and obesity (16.5%). There were significant differences in the prevalence of CVD risk factors among geographical regions. The prevalence of at least one risk factor across regions was as follows: North America, 70.0%; Europe/Australia/Israel, 65.1%; South America, 49.4%; Asia, 37.0%; Africa, 55.8% (P-value < 0.001). Significant regional differences were also observed when risk factors were used as part of the Framingham and Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) risk scores or used to define a favourable risk profile. CONCLUSIONS CVD risk factors are common among START participants, and their distribution varies by geographical region. Better understanding of how and why CVD risk factors develop in people with HIV infection and their geographical distributions could shed light on appropriate strategies for CVD prevention and may inform the interpretation of the results of START, as CVD is expected to be a major fraction of the primary endpoints observed.
Collapse
Affiliation(s)
- E Z Soliman
- Epidemiological Cardiology Research Center (EPICARE), Department of Epidemiology and Prevention, and Department of Internal Medicine-Cardiology, Wake Forest School of Medicine, Winston Salem, NC, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Mease P, Etzel C, Kremer J, Deveikis S, Li Y, O'Connor J, Kavanaugh A, Ruderman E, Curtis J, Ritchlin C, van der Heijde D, Solomon D, Greenberg J. AB1157 Characteristics of a US Psoriatic Arthritis/Spondyloarthritis Cohort: Baseline Data from the Corrona PSA/SPA Registry. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
50
|
Cocke M, Moerke M, O'Connor J, McMahon L. Hypothermic Effects of Δ
9
‐THC and Nicotine in Kynurenine‐3‐Monooxygenase (KMO) Knockout Mice. FASEB J 2015. [DOI: 10.1096/fasebj.29.1_supplement.lb491] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Morgan Cocke
- Department of PharmacologyUniversity of Texas Health Science Center at San AntonioSan AntonioTexasUnited States
| | - Megan Moerke
- Department of PharmacologyUniversity of Texas Health Science Center at San AntonioSan AntonioTexasUnited States
| | - Jason O'Connor
- Department of PharmacologyUniversity of Texas Health Science Center at San AntonioSan AntonioTexasUnited States
| | - Lance McMahon
- Department of PharmacologyUniversity of Texas Health Science Center at San AntonioSan AntonioTexasUnited States
| |
Collapse
|